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ABSTRACT 
Uremic pruritus (UP) arises in end-stage renal disease (ESRD) and is not relieved by 
proper dialysis. While the pathogenesis of UP is not well understood, UP responds poorly 
to anti-histamines. We performed a case-control study to test if cutaneous protease-
mediated, non-histamine itch is augmented in UP, and if UP is associated with altered 
epidermal and/or papillary dermal innervation. We recruited 12 hemodialysis subjects 
with ESRD-specific itch (cases) (Visual Analogue Scale (VAS)-average itch in the 
preceding week, 78/100), and 13 age- and sex-matched hemodialysis subjects without 
pruritus (controls) (VAS- average itch in the preceding week, 0/100; p<0.0001 cases vs. 
controls). Cowhage spicule-induced itch was induced in the back where all subjects 
exhibited itch, and the entire duration of itch was measured with the general Labeled 
Magnitude Scale. Subsequently, a punch biopsy was taken from this sensory-tested skin 
and multi-label immunohistochemistry was performed to measure epidermal and 
papillary dermal innervation. In cases vs. controls, cowhage-induced area under the curve 
(AUC) for itch was significantly larger (median, 25%–75%: 175.4, 101.0–252.2 vs. 42.4, 
24.0–160; p=0.04) as was perceived peak itch intensity (53.6, 53.3–78.9 vs. 34.2, 20.9–
55.6; p=0.02). Cases showed a significant reduction in papillary dermal nerve length 
  viii 
(PDNL)/mm epidermis (2295, 1659–2970 vs. 2909, 2228–3523; p=0.003), resulting from 
the loss of papillary dermal (PD)-calcitonin gene related peptide (CGRP) (+) nerves 
(p<0.0001), with preservation of %PD-substance P (+) nerves (p=0.1) and intraepidermal 
nerve fiber density (p=0.1). VAS-average itch in the preceding week negatively 
correlated with PDNL/mm epidermis (correlation coefficient (CC)=-0.53, p=0.003) and 
%PD-CGRP (+) nerves (CC=-0.37, p=0.03). Cowhage-induced AUC-itch negatively 
correlated with %PD-CGRP nerves only in cases (CC=-0.40, p=0.02). Our data suggest 
augmented protease-dependent signaling contributes to UP and indicate a mechanism for 
how PD-CGRP (+) nerve loss contributes to UP and augmented cowhage-itch: loss of an 
afferent skin-derived itch-inhibition signal to the spinal cord dorsal horn. 
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CHAPTER 1. INTRODUCTION 
This study investigates the cutaneous pathophysiology of uremic pruritus. The motivation 
for this study was the question—what causes and sustains chronic itch? This question 
originates from the clinical observance that chronic itch is as detrimental to patients as is 
chronic cancer pain. Several theories have been proposed to explain chronic itch based on 
the signaling pathways of specific peptides postulated in animal models to mediate itch 
sensation. Because chronic itch states are heterogeneous, no one signaling pathway will 
account for all types of clinical chronic itch. Uremic pruritus was selected as the study 
objective because of its clinical relevance and relative lack of efficacious clinical 
treatment options. Uremic pruritus arises in the setting of kidney disease. Numerous 
confounding metabolic abnormalities can contribute to itch in this patient population. 
Nevertheless, in a significant subset of subjects with kidney failure, pruritus will persist 
despite their adequate correction, including proper dialysis and resolution of both 
hyperparathyroidism and ion-derangements. We defined this persistent itch as true 
uremic pruritus as it serves as a model for chronic itch in the absence of cutaneous 
inflammation. 
 
In Chapter 2, I briefly review the extant literature, identify gaps in our current 
understanding of the causes of uremic pruritus, and articulate the hypotheses. In Chapter 
3, I delineate specific aims of the study. In Chapter 4, I discuss the research design and 
methodological strategies. In Chapter 5, I present the findings in two parts: Part 1 focuses 
on the statistical analysis of data from clinical questionnaires, cutaneous sensory tests and 
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cutaneous nerve quantifications; Part 2 provides images of multi-label 
immunohistochemistry with different markers in the skin and heart. Chapter 6 theorizes 
the findings, discusses the contributions of this work to academia and clinical practice, 
reflects on the limitations of the data, and pinpoints directions for future studies. Chapter 
7 concludes the dissertation by summarizing the main themes of the study. 
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CHAPTER 2. LITERATURE REVIEW  
This chapter reviews the classifications of itch and the different putative itch mediators 
and signaling pathways proposed to be involved in uremic pruritus. This chapter also 
states our hypotheses, and provides underlying evidence and rationale, for the possible 
causes of uremic pruritus. 
 
2.1 Pruritus: Definition and Classification 
Defined by German physician Samuel Harfenreffer more than three centuries ago (Dhand 
and Aminoff, 2013), pruritus is an unpleasant sensation that provokes the desire or reflex 
to scratch. Itch has been classified into three mechanistic categories: pruriceptive itch, 
neurogenic itch, and neuropathic itch (Ikoma et al., 2006). Pruriceptive itch is induced 
from peripheral mechanisms within a healthy nervous system. Neurogenic itch is induced 
from central mechanisms within a healthy nervous system. Neuropathic itch is caused by 
diseased neurons (Ikoma et al., 2006).  
 
Clinically, acute itch is defined as itch that lasts less than six weeks, while chronic itch 
lasts more than six weeks (Dhand and Aminoff, 2013). More clinically significant, 
chronic itch has been divided into itch related to skin disorders, e.g. atopic dermatitis, 
psoriasis, and chronic urticaria, etc.; itch related to systemic disorders, e.g. chronic renal 
failure and chronic liver disease; itch secondary to psychological causes, e.g. delusional 
parasitosis; and itch related to neuropathic mechanisms, e.g. brain tumors from central 
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nervous system or post-herpetic itch from the peripheral nervous system. Skin-disorder 
chronic itch is thought to be pruriceptive with abnormal activity or sensitivity of primary 
afferent skin neurons (i.e., neurons in the skin that send signals into the spinal cord). 
Systemic-disorder chronic itch may arise from a combination of pruriceptive and 
neurogenic mechanisms. Uremic pruritus, a chronic itch, responds to treatment with 
narrow band ultraviolet light B (nbUVB), supporting a pruriceptive mechanism (Ada et 
al., 2005). However, uremic pruritus also can be treated by μ-opioid antagonists and κ-
opioid agonists, indicating a neurogenic mechanism as well (Odou et al., 2001; Wikstrom 
et al., 2005).  
 
Itch can also be sub-divided based on the efficacy of anti-histamine medication therapy 
into histamine-dependent and histamine independent pruritus. Histamine-dependent itch 
will occur in the setting of the cutaneous "axon flare", which is a triple response 
consisting sequentially of vasodilation, flare and wheal. Anti-histamine treatment is 
effective for some causes of acute itch, such as urticaria, acute insect bite reactions, and 
mastocytosis. However, most chronic itch conditions, including uremic pruritus, are not 
responsive to systemic anti-histamines, but non-histamine itch mediators for these 
chronic itch conditions are not well characterized. 
 
2.2 Neuroanatomy of Cutaneous Innervation 
2.2.1 Classification of Primary Afferent Nerves in the Skin 
Peripheral sensory nerves are composed of A- and C-fibers. Subsets of both A-δ fibers, a 
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sub-type of A-fibers, and C-fibers both convey the sensation of itch. C-fibers make up 
about 20% of primary afferent fibers. In contrast, A-δ fibers, the other set of itch-
mediating nerve fibers, account for 80% of all post-ganglionic A-fibers (Lawson, 2002).  
 
2.2.1.1 A fibers 
A fibers are classified into α, β, and δ subtypes. Skin is innervated by β and δ fibers, 
whereas A-α fibers mediate sensory innervation of muscles (Lawson, 2002). A-α fibers 
are the thickest myelinated and with the highest conductivity.  
 
A-β fibers are moderately thick myelinated nerve fibers that innervate touch receptors. 
They are low threshold mechano-receptors for detection of vibration and slight 
indentation. They are also the nerves making up nerve end organs such as Meissner's 
corpuscles, Merkel cell neurite complexes, Pacinian corpuscles, and Ruffini endings. A-β 
mechanoreceptors also play an important role in mediating pain from non-painful 
stimulation (pain central sensitization) upon sensitization from capsaicin. (Baron et al., 
2000). 
 
A-δ fibers are thinly myelinated with the slowest conducive velocity among A fibers. 
However, they can have as long as 5cm unmyelinated branches in the skin which make 
them difficult to differentiate from cutaneous C-fibers (Peng et al., 1999). Both A-δ fibers 
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and C-fibers mediate thermal and nociceptive sensations. A-δ fibers can be subdivided 
into classes of fibers for cold sensitivity (A-δ cold) and nociceptive feelings. As 
nociceptive receptors, A-δ fibers are further divided into those with a high threshold for 
mechanical stimulation (mechano-insensitive) and those that are mechano-heat sensitive 
(Aδ-MH) (Schmelz 2011). Aδ-MHs are responsible for heat and burning pain from heat 
sensation, which A-δ cold fibers can suppress (Campero et al., 2009). 
 
2.2.1.2 C Fibers  
C fibers are thin and unmyelinated with slow conductivity. They are classically involved 
in the warm sensation (C-warm fibers) and nociceptive sensations (Schmelz 2011). They 
are also implicated in emotional or limbic touch in the recent literature (Essick et al., 
1999). C nociceptors are further divided into polymodal C-nociceptors and mechano-
insensitive C-nociceptors (Schmelz 2011). Polymodal C nociceptors respond to a variety 
of different types of painful modalities (Ma, 2010) and can be classified as 1) C-cold 
fibers that respond to innocuous cold but also to hot burning pain; 2) C2 fibers capable of 
detecting both heat and cold; 3) CH responding to noxious heat; 4) CMHC fibers that are 
sensitive to noxious mechanical, heat, and cold; and 5) CMH that respond to both 
mechanical stimuli and heat. Interestingly, subsets of CMH fibers also mediate 
histamine-independent itch (Johanek et al., 2008). Mechano-insensitive C-nociceptors 
have a higher activation threshold for heat and do not respond to mechanical stimuli. This 
subset of C fibers is also termed heat- and mechano-insensitive C fibers (CMiHi). 
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Mechano-insensitive histamine-responsive C fibers (CMiHis+) comprise about 10% of 
CMiHi fibers and are activated by histamine with durations of activation and receptive 
fields matching the histamine-itch duration and flare area (Schmelz et al., 1997).  
 
2.2.2 Neuroanatomy of Itch 
Itch sensation is transmitted from the skin to the spinal cord by small diameter, 
unmyelinated C-fibers and thinly myelinated Aδ-fibers (Ringkamp et al., 2011; Schmelz, 
2010). In human skin, C‐fibers that mediate pruritus are either mechano‐insensitive, 
histamine‐responsive nerves (CMiHis+) or mechano- and heat-sensitive, polymodal 
nociceptors (CMH) which are unresponsive or only weakly responsive to histamine 
(Ringkamp et al., 2011; Schmelz, 2010). Accordingly, CMiHis+ neurons mediate 
histamine-dependent itch while CMH neurons mediate at least some types of non-
histamine dependent itch (Johanek et al., 2008).  
 
The central nervous system pathway that mediates itch begins in the dorsal horn of the 
spinal cord with the synapse formed by the afferent primary cutaneous nerve (i.e., going 
from the skin into the spinal cord) and the second order neuron dendrites. These second 
order neurons either are interneurons that in turn synapse with neurons located in deeper 
layers of the dorsal horn or are projection neurons that send axons to the contralateral 
spinothalamic tract to terminate on third-order neurons in the thalamus. From the 
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thalamus, the signal is then projected diffusely to cortical and subcortical regions (Fig. 2-
1, 2-2) (Dhand and Aminoff, 2013).  
 
2.2.2.1 CMiHi Nerves  
CMiHi nerves have higher electrical activation thresholds than polymodal C-nociceptors 
(Ikoma et al., 2005). When CMiHi nerves are activated in human skin, the axon reflex is 
observed, consistent with histamine-induced itch. However, the H1 histamine receptor, 
responsible for histamine-induced itch, was shown to be essential for pain mediation in a 
mouse model (Mobarakeh et al., 2000). CMiHi was also shown to be involved in central 
sensitization of pain (Schmelz, 2000). Therefore, CMiHi are involved in transmitting 
both histamine-dependent itch and pain.   
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Figure 2-1. Peripheral Anatomy of Itch (Dhand and Aminoff, 2013). 
 
The histamine-dependent (red) and histamine-independent (blue) itch pathways and the 
peripheral pain pathway (green) are shown. Histamine-dependent itch is induced by 
cutaneous application of histamine and transmitted via cutaneous mechanically 
insensitive C-fibers. Histamine-independent itch can be induced by numerous cutaneous 
stimuli, including cowhage, and is transmitted via cutaneous polymodal C-fibers. Itch 
modulation by pain has be postulated in mice to be partially mediated by Bhlbb5 
interneurons in the dorsal horn of the spinal cord. STT = spinothalamic tract; Bhlbb5 = 
transcription factor protein; CMi = mechano-insensitive C-fibers; C-polymodal = 
polymodal C-fibers. (Figure from Dhand and Aminoff, 2013; legend adapted from Dhand 
and Aminoff, 2013) 
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Figure 2-2. Central Anatomy of Itch (Dhand and Aminoff, 2013). 
 
Second and higher order itch fibers for histamine (red) and cowhage (blue) travel in the spinothalamic tract to the thalamic nuclei (listed in the left box) usually contralateral to the stimulus. Cowhage neurons project to 
a broader set of nuclei than histamine neurons. In cowhage itch, thalamic neurons project to multiple cortical and subcortical structures (listed in the right box) with a broader and more diffuse pattern. These structures 
are usually activated in a bilateral and symmetric pattern, except that the insular cortex, claustrum, basal ganglia, and putamen have a minor emphasis contralateral to the stimulus. STT = spinothalamic tract. (Figure 
from Dhand and Aminoff, 2013; legend adapted from Dhand and Aminoff, 2013) 
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2.3 Histamine-Independent Itch: Protease Pathway  
In human skin, itch independent of histamine mediation is defined as itch without an 
accompanying axon-reflex erythema (Ikoma et al., 2005). Cutaneously-applied proteases 
can generate pruritus in a histamine-independent manner. Therefore, protease signaling 
has emerged as an effective marker for the histamine-independent, peripheral itch-
signaling neuronal pathway (Steinhoff et al., 2003).  
 
Cowhage spicules derived from the pod of the bean plant Mucuna pruriens, when 
inserted into the skin at the level of the dermoepidermal junction, elicit an intense itch 
sensation admixed with milder pricking/stinging and burning sensations (LaMotte et al., 
2009). The active pruritogenic component of cowhage is mucunain (Shelley and Arthur, 
1955), a cysteine protease (Reddy et al., 2008).  Cowhage-induced itch has been 
proposed as a clinically useful tool to assess histamine-independent itch (LaMotte et al., 
2009; Ikoma et al., 2006). Cowhage spicules induce cutaneous sensations when the tip is 
inserted into the skin to a depth that terminates approximately at the dermal-epidermal 
junction to depths of around 200μm into the papillary dermis (Papoiu et al., 2011).  
Histamine-independent, cowhage-induced itch activates polymodal CMH and Aδ-fibers 
that project to a population of ascending spinothalamic tract (STT) neurons distinct from 
those activated by histamine (Davidson et al., 2007; Namer et al., 2008) 
 
The cowhage cysteine protease mucunain activates the G protein-coupled receptors, 
protease-activated receptors (PARs) 2 and 4 (Reddy et al., 2008). Evidence showed that 
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PAR-2 and transient receptor potential vanilloid 1 (TRPV-1) are co-expressed in 90% of 
all TRPV-1 expressing C-fibers. PAR-2 can sensitize TRPV-1 and induce thermal 
hyperalgesia (Amadesi et al., 2004). PAR-2 is also involved in inflammation and 
subsequent hyperalgesia (Cottrell et al., 2003). PAR-2 expression is therefore involved in 
nerves that mediate both itch and pain. 
 
Human epidermis expresses endogenous cysteine proteases, such as those of the 
cathepsin family, including cathepsin S, cathepsin V, and cathepsin L (Reddy et al., 
2010). Specifically, cathepsin S was shown to be pruritic when injected into human skin 
(Reddy et al., 2010). While cathepsin S is an endogenous agonist of PAR-2 and 4 (Reddy 
et al., 2010), this (and possibly other) proteases may be mediating histamine-independent 
itch using receptors beyond PARs. Specifically, cathepsin S, can induce itch via 
activation of a different class of G protein-coupled receptors, the Mas-related G-protein-
coupled receptor (Mrgpr), Mrgpr C11 (Reddy et al., 2013). In mice skin, different Mrgprs 
mediate distinct chemical itch sensations, and the neurons that express these receptors 
transmit itch sensation to the spinal cord (Dong et al., 2001). Mrgprs have human 
homologues, and their ligands, such as the bovine adrenal medulla 8-22 (BAM8-22) 
peptide [a proteolytic cleavage product of proenkephalin A], chloroquine, SLIGRL (also 
a ligand of PAR-2), and β-alanine, induce itch in humans (Sikand et al., 2011; Liu et al., 
2009; Lembo et al., 2002). Mrgprs could potentially represent another marker for a subset 
of histamine-independent itch nerves.    
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2.4 Mechanism of Chronic Itch  
Two possible pathophysiologic states have been proposed to explain chronic itch: 
peripheral sensitization and central sensitization. Peripheral sensitization is the decreased 
activation threshold and increased basal activity of cutaneous itch-signaling nerve fibers 
(Dhand and Aminoff, 2013). Central sensitization results from the neuroplasticity that 
occurs in the spinal cord and brain such that non-pruritic cutaneous stimuli are perceived 
as, or augment, the sensation of itch (Dhand and Aminoff, 2013).  
 
2.4.1 Central Sensitization   
Specifically, in the spinal cord, itch and pain processing can be centrally sensitized such 
that touch stimuli evoke itch (alloknesis) or pain (allodynia) or that punctate mechanical 
stimuli evoke more intense pricking pain (punctate hyperalgesia) or itch (punctate 
hyperknesis). Moreover, normally painful stimuli can be misinterpreted as itch in chronic 
itch patients (‘‘pain alloknesis’’) or normally itch-inducing stimuli can be mistaken as 
pain in chronic pain patients (‘‘itch allodynia’’) (Figure 2-3) (Ikoma et al., 2006).  
 
Experiments have provided evidence supporting the role of central sensitization in itch 
onset. In mice, genetic ablation of the transcription factor Bhlhb5, a marker for inhibitory 
neurons (Figure 2-1), induced a scratching phenotype, interpreted as itch (Ross et al., 
2010;). These authors showed this scratching phenotype arose due to the loss of 
inhibitory neurons in the dorsal spinal cord (Ross et al., 2010).  
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Clinical and/or experimental tests for central sensitization include application to the skin 
of brush-strokes, pinpricks from a graded set of weighted needles, and the application of 
defined thermal stimuli (Ikoma et al., 2004; Sikand et al., 2009). 
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Figure 2-3. Mediators and the Sensitization Patterns of Nociceptive and 
Pruriceptive Neurons (Ikoma et al., 2006). 
 
Central sensitization in the pain (blue) and itch (red) pathways. Mediators can 
predominantly sensitize and activate itch pathways (red) or pain pathways (blue) or both 
itch and pain pathways equally (yellow). In the spinal cord, for each class of cutaneous 
nerve, incoming painful input can generate central sensitization for pain and incoming 
pruritic signals can provoke central sensitization for itch. Thus, for central sensitization to 
touch, amyloid-β (Aβ) fibers generate allodynia for pain versus alloknesis for itch; A-δ 
fibers generate punctate hyperalgesia for pain versus punctate hyperknesis for itch; and 
for C-fibers histamine-induced pain versus algogen-induced itch. ACh, acetylcholine; 
CGRP, calcitonin-gene-related protein; H+, hydrogen ion; IL, interleukin; NGF, nerve 
growth factor; SP, substance P; TNF, tumor necrosis factor. (Figure from Ikoma et al., 
2006; legend adapted from Ikoma et al., 2006) 
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Brush stroke test examines for alloknesis or allodynia that are thought to be mediated by 
low-threshold mechanoreceptors (Aβ fibers), requiring ongoing activity of nociceptive C 
fibers (Ikoma et al., 2006). After single cowhage application, more than 40% of healthy 
subjects experienced alloknesis (Sikand et al., 2009). This suggests that cowhage may 
activate central mechanisms of itch sensation.  
 
Pin-prick test examines punctate hyperalgesia or punctate hyperknesis that are thought to 
be induced by nociceptive C fibers and mediated by Aδ fibers (Ziegler et al., 1999). Pin-
prick is sensed as mildly painful in normal controls. The pain increases as the weight load 
increases, with the maximum pain less than 4 on a numeric scale ranging from 0 (no 
sensation) to 10 (maximal sensation imaginable) (Ikoma et al., 2004). Punctate 
hyperknesis was seen in lesional skin in 75% of atopic dermatitis patients with itch rating 
≥2 on the 0–10 scale. (Ikoma et al., 2004).  
 
Thermal test examines for pain alloknesis that is thought to be mediated by Aδ- and C- 
fibers (Ikoma et al., 2006). Metal rod preheated to 49 °C is sensed as noxious pain in 
normal controls. The maximum pain was 3.5 on the above 0–10 scale (Ikoma et al., 
2004). This noxious heat was also sensed as itch in lesional skin of atopic dermatitis 
subjects, with the maximum itch of 2.5 on the 0–10 scale (Ikoma et al., 2004).  
 
2.4.2. Central Sensitization and Uremic Pruritus 
Evidence suggests that central sensitization also contributes to uremic pruritus. Unlike 
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atopic dermatitis, the skin in uremic pruritus lacks observable inflammation. Systemic 
circulating itch signals and/or toxin(s) may be present, bypassing the peripheral nerves 
and acting directly in the dorsal horn of the spinal cord to either elicit itch or generate 
inappropriate itch-sensations to otherwise non-pruritic cutaneous stimuli. Opioids are one 
such systemic itch signaling-candidate. Mu-opioids, such as morphine, facilitate itch 
sensation, and kappa-opioids, such as dynorphin, reduce itch (Stander and Schmelz, 
2006; Togashi et al., 2002). However, studies correlating beta-endorphin (a mu-agonist) 
levels with itch intensity in uremic pruritus have been mixed with one study showing a 
positive correlation and the other, no correlation (Odou et al., 2001; Mettang et al., 1998). 
Moreover, nalfurafine, a kappa agonist, showed only modest itch reduction in ESRD 
subjects on hemodialysis. The itch reduction in nalfurafine 5mg group was 32–37% 
compared to a 20% decrease in the placebo group (Wikstrom et al., 2005; Kumagai et al., 
2009). As we have discussed extensively in the 2.9 Uremic Pruritus section, the role of 
systemic opioids in pathogenesis of uremic pruritus has not been well-established, 
opening the possibility for other non-opioid systemic-acting itch mediators.  
 
Nearly all intraepidermal nerve fibers (IENFs) in human epidermis are TRPV-1 positive 
(i.e., capable of sensing at least pain). All markers to date of itch sensing neurons in 
human skin (including BNP/BNP precursor expressing nerves) terminate predominantly 
at the DEJ (and not in the epidermis). In some inflammatory skin conditions 
characterized by pruritus (such as lichen amyloidosis and nummular dermatitis), IENFs 
are lost despite relative preservation of the DEJ nerves (Maddison et al., 2011; Maddison 
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et al., 2008). Thus, pathologic itch may arise from loss of intraepidermal pain nerves with 
preservation of DEJ itch signaling fibers (Timmes et al., 2013).   
 
Moreover, it is also not known whether or not papillary dermal cutaneous nerves, 
expressing itch-signaling markers, are involved in uremic pruritus. One study, with 
significant methodological issues, reported a decrease of both epidermal nerves and 
CGRP-positive nerves at the DEJ in human skin after nbUVB or UVB+UVA treatment 
for eczema (Wallengren and Sundler, 2004).   
 
2.4.3 Peripheral Sensitization 
Evidence for peripheral sensitization of protease-mediated nerve signaling in human 
pruritic skin diseases is lacking. In normal subjects, cowhage spicule induced-itch lasts 
on average about 15 minutes and has usually completely and spontaneously resolved after 
30 minutes after onset (Sikand et al., 2009). In some patients with atopic dermatitis, the 
duration of itching lasted up to one hour (Arthur and Shelley, 1958). 
 
2.4.4. Peripheral Sensitization and Uremic Pruritus 
Clinical experience with experimental treatments for uremic pruritus indicates that 
peripheral sensitization of itch-signaling cutaneous nerves contributes significantly to 
uremic pruritus. Specifically, topical capsaicin and narrow band UVB phototherapy, 
treatments that target cutaneous nerves and/or keratinocytes that can directly signal to 
these nerves, alleviated uremic pruritus. Topical application of capsaicin opens the 
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TRPV-1 ion channel, and over time, the resulting influx of divalent ions leads to 
degeneration of the terminal ends of these axons (Sharma et al., 2013). Several small 
double-blinded studies have suggested that topical capsaicin-induced chemodenervation 
of TRPV-1 epidermal and DEJ nerves partially relieved uremic pruritus (Breneman et al., 
1992; Makhlough, 2010; Cho et al., 1997). One study found a reduction from moderate-
to-severe to minimal-to-none (8 of 9 patients, no placebo control) (Breneman et al., 
1992). In a second study that was double-blinded and placebo-controlled, of 5 patients, 2 
had complete resolution of itch and 3 had mild-to-moderate improvement. There was no 
change in itch on the placebo-treated area (Breneman et al., 1992). Another randomized 
double-blinded crossover clinical trial was performed on 34 patients and used a 
complicated measure for itch, but found that topical capsaicin reduced the itch from a 
rating of ~16 to 2.5 vs. placebo that reduced itch from ~15 to 7.2 (p<0.001) (Makhlough, 
2010). Finally, in a double blinded, cross-over study, of 22 subjects treated with topical 
capsaicin, 19 responded to capsaicin while 5 responded to placebo (Cho et al., 1997). 
 
Second, phototherapy utilizing narrow-band UVB is a clinically effective treatment to 
relieve uremic pruritus, with a reported response rate of ~50% to 80% in various studies 
with small sample sizes (Ee et al., 2006; Ada et al., 2005). While the mechanism(s) by 
which nb-UVB treats pruritus is(are) not well-understood, phototherapy with nb-UVB 
utilizes the wavelengths 311–313 nm to treat skin disease. These wavelengths can 
penetrate the superficial layers of the skin at the levels epidermis and papillary dermis. 
Thus, efficacy of topical capsaicin and nb-UVB suggests keratinocytes (in the epidermis) 
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as well as itch-sensing nerves that reside in the papillary dermis and possibly the 
epidermis, are targets to reduce peripheral sensitization.  
 
While TRPV-1 expression or putative inhibition by nb-UVB does not distinguish 
between nerves that signal histamine and non-histamine-mediated itch, uremic pruritus 
responds poorly or not at all to anti-histamines (Weisshaar et al., 2003). Moreover, 
increased plasma histamine levels in uremic patients have been detected in some but not 
all studies, and no relationship was found between plasma histamine level and severity of 
pruritus (Weisshaar et al., 2003). Thus, clinical and experimental evidence suggests the 
histamine pathway is not active in this type of chronic itch.  
 
2.5 Peptidergic Itch Markers (CGRP, SP, NPPB)  
In the spinal cord dorsal horn, neurotransmitters such as calcitonin gene related peptide 
(CGRP), gastrin-releasing peptide (GRP), substance P (SP), and glutamate have been 
implicated as mediators of the first itch synapse (Davidson and Giesler, 2010). Glutamate 
is known to be the principle fast neuron transmitter in primary afferent neurons (Rogoz et 
al., 2014). Molecular markers of nociceptive neurons are divided into non-peptidergic 
and peptidergic (Rogoz et al., 2014). CGRP and SP are known to be the peptidergic 
markers of nociceptive neurons (Snider and McMahon, 1998). Recent experiments in 
mice raised the possibility that Brain Natriuretic Peptide (BNP) and/or its precursors, 
may also be novel itch mediators and so molecular markers of itch-sensing nerve 
pathways (Mishra and Hoon, 2013). 
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2.5.1 Substance P (SP)  
Substance P was the first discovered neuropeptide in mammals and is a member of the 
tachykinin neuropeptide family. SP has been recognized as a neurotransmitter of primary 
afferent nerves since the 1950's, its endogenous receptor is the neurokinin 1 receptor 
(NK1-receptor, NK1R). SP is a neuropeptide widely distributed in the peripheral and 
central nervous system. In the peripheral nervous system, SP is synthesized in the cell 
bodies of C-fibers, and its release into the skin causes vasodilatation and increased 
vascular permeability. 
 
SP is also thought to intensify itch perception. Intradermal injection of SP provokes itch 
as well as characteristics of neurogenic inflammation such as erythema, wheal, and flare 
(Hagermark et al., 1978). However, endogenous release of SP does not lead to mast cells 
degranulation in healthy human skin (Schmelz et al., 1999) or induce itch at 
physiological concentrations (Weidner et al., 2000). However, low concentrations of SP 
can sensitize NK1R on mast cells, leading to increased production of tumor necrosis 
factor (TNF-α) (Cocchiara et al., 1999). In turn, TNF-α sensitizes nociceptive nerve 
endings.  
 
SP is co-localized with other neurotransmitters, such as serotonin, dopamine, or CGRP, 
and acts as a neuromodulator. SP is elevated in plasma in atopic dermatitis patients 
compared to controls and correlates with disease activity (Toyoda et al., 2002). On the 
other hand, SP has been found to play an important role in the induction of pain and 
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hyperalgesia in rodents (Laird et al., 2001), although there is little evidence for the 
clinical analgesic efficacy of the antagonists of its receptor NK1R (Hill, 2000). However, 
the NK1R antagonist Aprepitant has been shown to alleviate itch in patients with Sezary 
syndrome, solid tumors, or with chronic pruritus related to various systemic diseases 
(Duval and Dubertret, 2009; Vincenzi et al., 2010; Stander et al., 2010). Thus, SP 
signaling is involved in both itch and pain signaling pathways. SP might contribute to 
itch by increasing neuronal sensitization and through its long-term interaction with mast 
cells (Yosipovitch et al., 2003). 
 
2.5.2 Calcitonin Gene Related Peptide (CGRP)  
CGRP belongs to the calcitonin family of peptides, which consists of at least six 
members, namely, calcitonin, amylin, intermedin, adrenomedullin, and CGRP (Poyner et 
al., 2002). CGRP is widely distributed in the peripheral and central nervous systems, as 
well as cardiovascular, respiratory and gastrointestinal systems (Arulmani et al., 2004). 
There are two isoforms of CGRP, α-CGRP and β- CGRP (Arulmani et al., 2004). α-
CGRP is preferentially expressed in sensory neurons (Rosenfeld et al., 1983). Other than 
acting as a neuropeptide, CGRP is a potent vasodilator (Brain et al., 1985). To date, 
CGRP is implicated in mediating both itch and pain.  
 
CGRP antagonists exhibit a promising future for treating migraines (Villalon and Olesen, 
2009). Although systemic infusion of CGRP has successfully induced migraine (Lassen 
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et al., 2002), CGRP does not cross the blood-brain barrier. The mechanisms by which 
CGRP antagonists treat migraines include inhibition of peripheral and central 
sensitization of pain and inhibiting vessel dilatation in the brain (Villalon and Olesen, 
2009). 
 
There are two forms of CGRP receptor antagonists: peptide CGRP8-37 and non-peptide 
(BIBN4096BS (Olcegepant) (Doods et al., 2000) and MK-0974 (Telcagepant) (Williams 
et al., 2006)). New CGRP receptor antibodies are under investigation. In rats, CGRP is 
involved in inducing morphine tolerance in treating nociceptive pain (Powell et al., 2000). 
Intrathecal injection of CGRP receptor antagonists (CGRP8-37 or BIBN4096BS) 
combined with morphine can counteract the tolerance seen when morphine was given 
alone. 
 
In the skin, CGRP is one of the most abundantly expressed neuropeptides and often is co-
localized with either SP or somatostatin (Gibbins et al., 1987). The exact role of CGRP in 
itch and pain remains to be elucidated. In rodents, CGRP has been implicated in itch 
signaling. Genetic ablation of CGRPα-expressing sensory neurons reduced sensitivity to 
itch that is induced by histamine and chloroquine, that activates mouse MrgprA3 and 
human MrgprX1 respectively, but did not impair β-alanine-induced itch that is associated 
with non-peptidergic sensory neurons (McCoy et al., 2013). 
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However, there is more evidence in rodents for CGRP in signaling pain. In rodent studies, 
CGRP was reported to mediate noxious heat (Mogil et al., 2005). Intrathecal injection of 
CGRP was reported to induce hyperalgesia and central sensitization for pain in rats (Sun 
et al., 2004). In mouse models of atopic dermatitis, the concentration of CGRP in the skin 
was decreased, at the same time SP was increased compared to controls. This observation 
supports the idea that CGRP mediates pain (i.e., by being reduced in a pruritus model) 
while SP mediates itch (ie, by being increased in a pruritus model) (Katsuno et al., 2003). 
Intensity of pain induced by noxious heat positively correlated with CGRP expression 
and sensitivity in mouse models (Mogil et al., 2005). In human studies, CGRP was 
significantly increased in the plasma in some chronic pain states, though no significant 
correlation was seen between pain rating and CGRP concentration in the plasma (Birklein 
et al., 2001). Thus, although CGRP may be involved in both itch and pain pathways in 
rodents, the data suggest CGRP has a greater role in nociceptive pain in both human and 
animal models (Ikoma et al., 2006). 
 
2.5.3 Natriuretic Polypeptide Precursor B (NPPB) 
Natriuretic polypeptide precursor B (NPPB) is the rodent analogue of the human Brain 
Natriuretic Peptide (BNP) precursor protein. In mice, NPPB was shown to be an itch-
specific neurotransmitter released by primary cutaneous somatosensory nerves to active 
itch-signaling neurons in the dorsal horn of the spinal cord that expressed its receptor, 
natriuretic peptide receptor A (NprA) (Figure 2-4) (Mishra and Hoon, 2013). In mice, 
blockage of NPPB signaling inhibited both histamine-dependent and histamine-
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independent itch (Mishra and Hoon, 2013). Therefore, while NPPB expression did not 
distinguish between these two signaling pathways, it nevertheless highlighted itch-
specific cutaneous sensory nerves. 
 
Figure 2-4. NPPB as an Itch-Specific Neurotransmitter (Mishra and Hoon, 2013). 
 
Neuroanatomical model of the itch-specific nerve pathway. Primary pruriceptive nerves 
release Nppb in the dorsal horn of the spinal cord to activate the Npra receptor on second 
order neurons. These activated second order neurons in turn utilize GRP as 
neurotransmitter to active third order neurons that express the GRP-receptor.  Nppb: 
Natriuretic Polypeptide B; Npra: natriuretic peptide receptor A; GRP: Gastrin-Releasing 
Peptide. (Figure from Mishra and Hoon, 2013; legend adapted from Mishra and Hoon, 
2013) 
 
 
The human BNP gene is first translated to pre-proBNP1-134 (AKA: pre-proNPPB1-134), 
then cleavaged to proBNP1-108 (AKA: proNPPB1-108) within cells. Upon excretion, 
proBNP1-108 is cleavaged to active BNP1-32 (AKA: NPPB1-32) and amino-terminal 
proBNP1-76 (NT-proBNP) (Figure 2-5) (Martinez-Rumayor et al., 2008). Active BNP1-32 
and proBNP1-108 can bind human NprA, and so are the most likely candidates to mediate 
itch (Stein and Levin, 1998).  
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Figure 2-5. Human BNP Metabolism (Martinez-Rumayor et al., 2008).  
 
Schematic model describing the synthesis and release of BNP.  BNP = B-type natriuretic 
peptide; DPP-IV = dipeptidyl peptidase–IV; NT-proBNP = amino-terminal pro–B-type 
natriuretic peptide. (Figure from Martinez-Rumayor et al., 2008; legend based on 
Martinez-Rumayor et al., 2008)  
  
27 
In humans, most BNP is excreted from heart muscle, including atria and ventricles. BNP 
synthesis and release from cardiac muscle is stimulated by mechanical stretching of this 
muscle, such as in conditions of volume overload, including congestive heart failure and 
kidney failure, as well as after ischemic injury, angiotensin II, and other pro-
inflammatory cytokines (Martinez-Rumayor et al., 2008). Active BNP signaling 
functions in humans to achieve potent natriuretic, diuretic and vasodepressor effects (de 
Bold et al., 1981). BNP signaling as a cause of itch in humans has not been shown to 
date. In this regard, nesiritide, a drug with the same structure as BNP1-32, caused pruritus 
in more than 1% of the study population during a clinical trial to treat decompensated 
congestive heart failure (Mills et al., 1997; http://dailymed.nlm.nih.gov/dailymed/ 
archives/fdaDrugInfo.cfm?archiveid=6077#section-8). Moreover, anecdotal case reports 
exist to indicate that acute heart failure is associated with significant pruritus (Javelle et 
al., 2011). Finally, BNP and NT-proBNP levels in uremic subjects are variably increased 
due to their accumulation secondary to loss of renal excretion (specifically for NT-
proBNP), cardiac co-morbidity, and volume overload (Satyan et al., 2007; Mallamaci et 
al., 2001; Tapolyai et al., 2013). The level of ProBNP1-108 in end-stage renal disease 
(ESRD) individuals has not been addressed in the medical literature to date, but a 
commercially available BNP assay can detect proBNP1-108 as well (Martinez-Rumayor 
et al., 2008). Recently, a study found a positive correlation between blood BNP levels 
and itch in hemodialysis patients (Shimizu et al., 2014). However, the design and conduct 
of this study has flaws detracting from the strength of this finding. This study determined 
both pre-and post-dialysis BNP values but only reported the mean of the post-dialysis 
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BNP level. The article used one of these two BNP levels for multiple regression analysis 
but did not specify which one was utilized. The BNP level used only correlated 
significantly with day-time and not nocturnal itch. However, if BNP is the systemic 
circulating molecule that induces itch, nocturnal itch should also have correlated with 
BNP levels as theoretically, enough time has passed post-dialysis for BNP to re-
accumulate. In addition, NPPB mRNA has been identified at low levels in human 
trigeminal ganglia and the BNP receptor NprA mRNA has been identified in the spinal 
cord dorsal horn (Goswami et al., 2014). Therefore, if BNP-expressing primary 
cutaneous nerves mediate itch through release into the human spinal cord, BNP/BNP 
precursors could then cause itch through peripheral sensitization as well.  
 
Recently, there has been some debate over whether NPPB was expressed in mice DRG. 
Although Mishra and Hoon exhibited NPPB staining in mice DRG, another group was 
unable to replicate this finding (Mishra and Hoon, 2013; Liu et al., 2014). A new study 
demonstrated NPPB mRNA in mice DRG, consistent with Mishra and Hoon, suggesting 
that NPPB could be the primary pruriceptive peptide (Solorzano et al., 2015). The 
existence of primary afferent NPPB/NPPB precursor-expressing sensory nerves in human 
skin was unknown. We have generated preliminary data proving the existence of 
NPPB/NPPB precursor expressing primary cutaneous neurons in human skin with an 
itch-sensing phenotype and anatomic location (Chapter 5. Findings, section 5.7.1). This is 
in accordance with the above described RNA-sequencing study in human trigeminal 
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ganglia (Goswami et al., 2014). However, their contribution, if any at all, to uremic 
pruritus is unknown. 
 
2.6 Transient Receptor Potential (TRP) Receptors 
TRP receptors respond to 'hot' and 'cold' and represent a superfamily involved in itch and 
pain. To date six groups of molecules complete this superfamily: (1) the canonical 
(TRPC), (2) the melastatin (TRPM), (3) the polycystin (TRPP), (4) the ankyrin 
transmembrane protein 1 (TRPA), (5) the mucolipin (TRPML), and (6) the vanilloid 
(TRPV) subfamilies. All members of this superfamily are nonselective calcium-
permeable sensory transduction channels (Clapham, 2003).  
 
The first and best-known is the TRP vanilloid receptor 1 (TRPV-1), activated by 
capsaicin, the pungent ingredient of hot chili peppers. Endovanilloids interact with 
TRPV-1 by activating or sensitizing TRPV-1 directly or indirectly (Caterina et al., 1997; 
Hwang et al., 2000). Endovanilloids constitute a group of itch mediators, such as 
eicosanoids, histamine, bradykinin, ATP, and various neurotrophins (NTs) (Chuang et al., 
2001; Hwang et al., 2000; Mohapatra and Nau, 2003; Shin et al., 2002).  
 
TRPV-1 expression in humans was first described on primary nociceptive afferent 
neurons (Caterina et al., 1997). TRPV-1-expressing nerves make up nearly 100% of the 
intraepidermal nerve fibers (IENF) and ~80% of the nerves at the papillary dermis 
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(Simone et al., 1996; Simone et al., 1998). Importantly, both histamine-dependent and 
histamine-independent nerve fiber pathways express TRPV-1, so responsiveness to 
capsaicin cannot distinguish these different classes in human skin (Sharma et al., 2013). 
Topical application of TRPV-1 agonist capsaicin has been used to treat both itchy and 
painful skin lesions; for example, brachioradial pruritus (Zeidler et al., 2015) and 
postherpetic neuralgia (Backonja et al., 2010). Clinically, the first days of the therapy are 
accompanied by a burning sensation and neurogenic inflammation, followed by a lasting 
depression of pain and itch. Other than action potential generation upon TRPV-1 
activation, neuropeptides are released, especially SP and CGRP (Caterina and Julius, 
2001). SP triggers plasma extravasation and CGRP triggers vasodilation, respectively. 
Under chronic activation, sensory nerve fiber stores of neuropeptides, such as substance 
P, are depleted, disrupting the communication between mast cells and skin sensory 
neurons (Yosipovitch et al., 2003). With chronic stimulation, TRPV-1 is desensitized in a 
Ca2+-dependent manner and leaves the nociceptive and pruriceptive neurons inactive. 
Moreover, the axonal transport of both neuropeptides and nerve growth factor (NGF) in 
the periphery is slower after chronic activation. Interestingly, TRPV-1 acts synergistically 
with the cowhage receptor PAR2 (Amadesi et al., 2006) and the SP receptor NK1R 
(Ikoma et al., 2006), which might have implications for the peripheral sensitization of 
itch and pain.  
 
Intradermal injection of capsaicin is always perceived as painful (Simone et al., 1989). 
Intradermal injection of capsaicin can also induce pain central sensitization (Sikand et al., 
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2011). In addition, loss of epidermal nerves from capsaicin application paralleled 
hypoalgesia (Nolano et al., 1999), indicating epidermal nerves also mediate pain. 
Interestingly, application of capsaicin to dermal-epidermal junction by deactivated 
cowhage spicules induces pruritus (Sikand et al., 2009). Moreover, itch was reported in 
more than 50% of subjects with topical application of capsaicin in one study (Green and 
Shaffer, 1993). Based on these data, TRPV1-expressing nerves that sense pain and itch 
are located in or near the epidermis whereas TRPV1-expressing nerves that only sense 
pain are located deeper in the dermis (Ma, 2010). Therefore, capsaicin receptor, TRPV-1, 
underlies a shared pathway of pain and itch but the ultimate sensation perceived from 
cutaneous activation of TRPV1-expressing nerves may depend on their anatomic location 
in the skin. 
 
TRPV-1 is also expressed in human epidermal and hair follicle keratinocytes (Stander et 
al., 2004), as well as mast cells and dendritic cells (Bodo et al., 2004). Upon activation, 
TRPV-1 can induce the release of cytokines from keratinocytes, which are involved in 
pruritus (Southall et al., 2003). Therefore, topically applied capsaicin may not only target 
nerve endings but may also provoke TRPV-1-mediated signaling in other non-neuronal 
skin cells to counteract a pruritogenic outcome.  
 
TRPV-1 signaling can also be modulated by skin inflammation. Skin inflammation 
decreases intradermal pH, and protons activate the TRPV-1 receptor. TRPV-1 stimulation 
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leads to the release of prostaglandin E2 (PGE2) and IL-8, that in turn aggravate the 
inflammation cascade (Southall et al., 2003).  
 
2.7 Itch Modulation (Pain Inhibits Itch) 
Pain and itch can be easily distinguished by both the sensations they evoke and the 
reverse reflex pattern. Pain triggers the withdrawal reflex leading to retraction, and 
therefore protection. Itch induces the scratching reflex to localize the affected skin site 
and draw attention to it.  
Scratching also represents a potentially damaging noxious stimulus. The inhibition of itch 
by painful stimuli has been shown experimentally using different types of painful stimuli, 
for example, heat, electrical current and mustard oil (Ward et al., 1996). Histamine-
induced itch was significantly reduced by painful electrical stimulation at a distance of up 
to 10 cm outside the stimulated site, suggesting a central mode of action (Nilsson et al., 
1997). Consistent with these results, histamine-induced itch including alloknesis and 
hyperknesis was suppressed inside the zone of capsaicin-induced allodynia (Brull et al., 
1999). This antagonism between pain and itch finds its ground in genetics: sensitivity in 
pain was inversely correlated to sensitivity in itch in mice strains (Green et al., 2006).  
 
2.8 Instruments to Measure Itch 
Several instruments have been designed to measure itch. Verbal rating scale (VRS) and 
visual analogue scale (VAS) have been the most used in the clinical setting. VRS and 
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VAS measure the absolute intensity of itch, whereas, the general version of the Labeled 
Magnitude Scale (gLMS) measures the comparative magnitude of the sensation.  
 
Specifically, VAS has been used for more than half a century to evaluate subjective 
symptoms. Subjects are presented with a 100mm horizontal line, with one end labeled as 
complete absence of the symptom, and the other end labeled as the worst symptom 
imaginable. Compared with VRS, VAS more closely assessed what a patient actually 
experienced with regard to change in sensory intensities (Ohnhaus et al., 1975).  
 
General version of the Labeled Magnitude Scale (gLMS) enables comparison of the 
perceived intensities of itch and nociceptive sensations on a common scale (LaMotte et 
al., 2009). The gLMS was an invention that combined the magnitude estimation and 
labeled scale estimation (Bartoshuk et al., 2004). Like the labeled scale, gLMS consisted 
of intensity descriptors, such as barely detectable at the lower end, weak, moderate, 
strong and very strong in the middle, with the strongest imaginable sensation of any kind 
at the other end. The labeled scale enables comparison between difference groups of 
sensation. Magnitude estimation provided a valid comparison independent of the 
measured sensation. The gLMS has been used to measure different nociceptive sensations 
(Green and Schoen, 2007).  
 
Different itch questionnaires were created to measure the quality of life that is affected by 
itch. Questionnaires with respect to specific skin diseases have been created, such as 
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psoriasis (Yosipovitch et al., 2000), chronic urticaria (Yosipovitch et al., 2002a), atopic 
dermatitis (Yosipovitch et al., 2002b) and uremic pruritus (Yosipovitch et al., 2001). 
Itchy QoL was a new questionnaire specifically targeting quality of life in patients with 
pruritus from various origins (Desai et al., 2008). Itchy QoL has two versions: bother and 
frequency versions. The itchy QoL questionnaire encompasses three sections based on 
the psychological conception of “quality of life”: emotions, functioning and symptoms. 
The content of itchy QoL questionnaire derived from in-depth patient interviews. This 
questionnaire was further validated in the clinical setting, confirming its reliability and 
sensitivity to changes in trial patients (Desai et al., 2008). The frequency version of itchy 
QoL questionnaire was used in our study.  
 
2.9 Uremic Pruritus 
2.9.1 Characteristics and Proposed Causes of Uremic Pruritus 
Pruritus is a prevalent symptom of individuals with end-stage renal disease (ESRD) on 
hemodialysis. Termed uremic pruritus, this symptom affects 22–90% of patients with 
ESRD and can severely affect quality of life, including sleep alteration and induction of 
both depression and anxiety (Feramisco et al., 2010; Zucker et al., 2003; Wang and 
Yosipovitch, 2010).  
 
Despite numerous proposed etiologic factors (Table 2-1), including inappropriate 
dialysis, xerosis, secondary hyperparathyroidism, derangement of divalent ions, such as 
phosphorus, defective sweating, and mast cell proliferation and degranulation, the 
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pathogenesis of uremic pruritus remains poorly understood (Keithi-Reddy et al., 2007; 
Szepietowski and Schwartz, 1998; Kumagai et al., 2012). Among all proposed causes of 
uremic pruritus, uremia, xerosis, anemia, hyperparathyroidism and high phosphorus and 
calcium levels are currently clinically proven itch causes. Despite clinical efforts to 
provide appropriate dialysis and correct the above abnormalities, some patients still have 
recalcitrant pruritus. In our study, we chose to study specifically this recalcitrant pruritus. 
  
Table 2-1. Proposed Causes of Uremic Pruritus 
Uremia 
Xerosis 
Anemia (iron, or Vitamin B12) 
Secondary Hyperparathyroidism 
Ion Derangement (Calcium, Phosphorus, magnesium, and aluminum) 
Defective Sweating 
Mast Cell Degranulation 
Retention of Poorly Dialyzable Molecules (e.g. morphine) 
Pro-Inflammatory Cytokines in The Skin 
 
2.9.1.1 Opioid as A Cause of Uremic Pruritus 
The role of systemic circulating opioids in uremic pruritus remains controversial. The 
dramatic resolution of itch after renal transplantation led to the theory that a poorly 
dialyzable pruritogenic molecule could be the culprit causing uremic itch. Systemic, 
circulating opioids, acting in the central nervous system (CNS), are possible candidates. 
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Various pain-relieving opioids were found to accumulate in renal failure, and no 
consensus exists if the parent opioid compounds and their metabolites can be adequately 
dialyzed by hemodialysis (Dean 2004). The most studied drug has been morphine. 
Morphine and its metabolites are effectively removed from the blood during 
hemodialysis, but their levels rebound as they re-equilibrate between the CNS and 
plasma. Specifically, morphine metabolites accumulate in the blood stream between 
dialysis sessions.  
 
Morphine activates the mu-opioid receptor (Ballantyne et al., 1988). Dynorphin activates 
the kappa-opioid receptor (Chavkin et al., 1982). In general, activation of mu-opioid 
receptors cause itch, while activation of kappa-opioid receptors has anti-pruritic effects. 
Studies correlating beta-endorphin (a mu-agonist) levels with itch intensity in uremic 
pruritus have been mixed with one study showing a positive correlation and the other, no 
correlation (Odou et al., 2001; Mettang et al., 1998). The efficacy of mu-opioid 
antagonists in treating uremic pruritus has been mixed as well (Andersen et al., 1984; 
Peer et al., 1996; Pauli-Magnus et al., 2000). Kappa-opioid agonists have shown mild-to-
moderate efficacy in treating uremic pruritus. The itch reduction in kappa-opioid agonist 
nalfurafine 5mg group was 32–37% compared to a 20% decrease in the placebo group 
(Wikstrom et al., 2005; Kumagai et al., 2009). Thus, further work is required to elucidate 
the contribution of opioids to the pathophysiology of uremic pruritus. In this study, 
subjects taking opioid drugs were excluded in both the case and control groups.  
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2.9.1.2 Immunological Alteration as A Cause of Uremic Pruritus 
Although there is no sign of inflammation in the skin of uremic pruritus. Immunological 
alteration, characterized by a pro-inflammatory pattern, is another theory proposed to 
explain uremic pruritus. In this theory, pro-inflammatory mediators, such as interlukin-2 
(that enhance the Th1 response), have been suggested to mediate uremic pruritus 
(Mettang et al., 2002). However, experimental results have been mixed. For example, 
tacrolimus ointment, which suppresses TH1 lymphocyte differentiation, showed dramatic 
relief of itch in a pilot study of 3 patients (Pauli- Magnus et al., 2000) but no efficacy in 
another controlled study (Duque et al., 2005).  
 
2.9.1.3 Other Postulated Causes of Uremic Pruritus 
Other less-well characterized mechanisms of uremic pruritus include antigen sensitization 
from dialysis, elevated levels of serum magnesium, plasma essential fatty acid 
abnormalities, aluminum overload, erythropoietin deficiency, and the serotonin theory 
(Kurban et al., 2007).  
 
2.9.2 ESRD Related Small Fiber Neuropathy 
The sensory symptoms in ESRD subjects follow a pattern of length-dependent, small-
fiber sensory neuropathy. Specifically, skin biopsies at the distal leg showed that IENF 
density is largely diminished in ESRD patients and negatively correlated with duration of 
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kidney disease (Lauria et al., 2010; Chao et al., 2011). There have not been any published 
articles to date reporting the relationship between IENF density and intensity of pruritus 
in either length-dependent or non-dependent areas, although one article observed a 
correlation between uremic pruritus and secondary neuropathy in ESRD subjects (Jedras 
et al., 1998). However, I could not evaluate the significance of these findings because 
only the abstract was available in English, and the abstract did not state how the 
relationship between uremic pruritus and secondary neuropathy was measured. 
 
2.10 Hypotheses  
2.10.1 Hypothesis 1: Uremic Pruritus is Partially Caused by Augmented Signaling 
Through the Histamine Independent, Protease-Activated Itch Pathway 
As described in the Literature Review chapter, (2.4.4), clinical experience with topical 
capsaicin and narrow band UVB phototherapy indicate that peripheral sensitization of 
itch-signaling cutaneous nerves contributes significantly to uremic pruritus. The lack of 
efficacy of systemic anti-histamines to treat uremic pruritus further suggests that the 
histamine-dependent pathway does not contribute to uremic pruritus.   
 
Whether peripheral sensitization of histamine-independent signaling cutaneous nerves 
contributes to uremic pruritus is unknown. We propose that histamine-indepndent 
protease-activated itch pathway is augmented in uremic pruritus. Cowhage-induced itch 
is a marker of histamine-independent itch pathway, but it has not been reported to date if 
alterations exist in cowhage responsiveness in the skin of uremic pruritus patients. To test 
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this hypothesis, we measured the time course and intensity of itch sensation from 
cowhage application in uremic pruritus and compared them with those in control 
subjects.  
 
2.10.2 Hypothesis 2: Uremic Pruritus is Partially Caused by Persistent Cutaneous 
Itch Fiber Signaling in the Setting of Decreased Itch-Inhibiting Cutaneous Pain 
Fiber Signaling 
As described in the Introduction chapter (2.4.2), evidence suggests that central 
sensitization also contributes to uremic pruritus Central sensitization to itch could arise 
by loss of itch-inhibiting spinal cord dorsal horn input from the selective loss of 
intraepidermal pain nerves with preservation of DEJ itch signaling fibers (Timmes et al., 
2013). However, it is not been well-established if neuroanatomical changes occur in itch 
and/or pain-sensing epidermal and papillary dermal nerves in uremic pruritus. 
 
To answer this question and test this hypothesis, we quantified epidermal nerves and 
papillary dermal nerves with different peptidergic markers for itch and/or pain in uremic 
pruritus subjects and compared them with those in controls.  
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CHAPTER 3. AIMS OF THE STUDY 
Hypothesis 1: Uremic Pruritus is partially caused by augmented signaling through the 
histamine independent, protease-activated itch pathway.  
(a) Specific Aim 1: Determine if cowhage-induced itch is augmented in uremic pruritus 
patients on hemodialysis compared to age- and sex-matched ESRD patients on 
hemodialysis without pruritus. 
(b) Specific Aim 2: Determine if itch induced by central sensitization tests (brush-stroke, 
pin-prick and thermal tests) is present in uremic pruritus patients on hemodialysis 
compared to age- and sex-matched ESRD patients on hemodialysis without pruritus. 
Hypothesis 2: Uremic pruritus is partially caused by persistent cutaneous itch fiber 
signaling in the presence of loss of itch-inhibitory cutaneous pain fiber signaling. 
(a) Specific Aim 1: Determine the percentage of BNP-expressing or SP-expressing or 
CGRP-expressing nerve fibers at the dermoepidermal junction (DEJ) in the skin of ESRD 
patients on hemodialysis with and without uremic pruritus. 
(b) Specific Aim 2: Determine the intraepidermal nerve fiber density (IENF) in the skin 
of ESRD patients on hemodialysis with and without uremic pruritus. 
(c) Specific Aim 3: Determine if there is a difference in the percentage of BNP-
expressing or SP-expressing or CGRP-expressing nerve fibers at the DEJ in the skin of 
ESRD patients on hemodialysis with and without uremic pruritus. 
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(d) Specific Aim 4: Determine if there is a difference in the IENF density in the skin of 
ESRD patients on hemodialysis with and without uremic pruritus. 
.
  
42 
CHAPTER 4. METHODOLOGY 
 
4.1 Study Design 
We performed a pilot study using a case-control design. All protocols were approved by 
Boston University Institutional Review Board (IRB) under the protocol number H-32330, 
and by DaVita Dialysis Center.  
  
4.2 Time Frame 
Subjects had a) one-time study visit lasting about 2.5 hrs and b) one optional suture 
removal visit.  
 
4.3 Subject Recruitment 
All English-speaking patients undergoing hemodialysis at DaVita Boston were informed 
individually about this study with the help of Dr. Jasvinder Bhatia. A flyer describing the 
study was also given to them. All staff and physicians working at DaVita Boston were 
informed about this study. Flyers (Appendix VII) describing the study were also placed in 
the waiting room of the Boston Medical Center (BMC) Dermatology outpatient clinic.  
 
All subjects having end-stage renal disease were undergoing hemodialysis at DaVita 
Boston. All patients undergoing hemodialysis at DaVita Boston were asked individually 
about their itch status and their willingness to participate in the study. Only those who 
expressed willingness to join the study were screened with the screening questionnaire 
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(Appendix I). Inclusion and exclusion criteria (Appendix II) were applied to all subjects 
that passed the screening. Only subjects that met the criteria were recruited. In addition, 
we excluded subjects complaining of itch only from their lower legs or distal arms. One 
subject initially presented with generalized pruritus and so was first scheduled to be a 
case subject. During screening, his source of pruritus was identified as xerosis and not 
uremic pruritus. This subject’s pruritus completely resolved after adequate 
moisturization. Subsequently, this subject was recruited into the control group. 
Recruitment was divided into two phases. Phase one was case-recruitment. Cases were 
defined as individuals with generalized uremic pruritus without other known causes and 
with a self-reported VAS score of average itch in the preceding week for itch of 30 or 
greater (out of 100), and concurrently on non-dialysis days. Phase two involved recruiting 
controls without pruritus who were age-and sex-matched with cases. Each individual 
control was selected to have an age range within 5 years of the matched case's age 
(Lauria et al., 2010).  
 
4.4 Study Visit 
Written consent took place in the outpatient Dermatology clinic at BMC. An IRB-
approved Informed Consent Form was presented to the subject, and the details of the 
procedures, risks, benefits, alternatives, costs, etc., were outlined. The subject was given 
the opportunity to ask any and all questions regarding the study. Each subject was given a 
photocopy of the signed written consent.  
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After subjects were consented to the study, all subjects 1) reported duration of 
hemodialysis. 2) completed the frequency version Itchy Quality of Life (QoL) 
questionnaire (appendix III) (Desai et al., 2008), and completed three Visual Analogue 
Scale (VAS) scores (Appendix IV) to assess pruritus: average itch in the preceding week, 
worst itch in the preceding week, and itch on the day of the visit; 3) underwent 4 non-
invasive tests of sensitization (described below); 4) underwent one 6 mm punch biopsy 
from itchy, normal-looking, non-scratched, non-eroded, non-ulcerated, lesion-free 
pruritic skin obtained from the lower back of all subjects to avoid length-dependent small 
fiber neuropathy (Chao et al., 2011).   
 
4.4.1 Methods to Test Sensitization 
Sensitization tests were performed on clinically normal-appearing pruritic skin located on 
the lower back close to the midline. Before the testing, subjects were taught the study 
definitions to describe cutaneous sensations, including itching, pain, burning, stinging, 
pricking, tingling, warm, and hot (Appendix V). Central sensitization tests included 
brush-stroke test, pin-rick test and thermal test.  
 
4.4.1.1 Assessment of Brush-Stroke Induced Sensation 
Test sites were stroked smoothly and lightly by a cotton swab attached to the end of a 
flexible coping saw blade at a rate of 1 Hz (Sikand et al., 2009). The participants were 
asked to report the evoked sensation (including presence of pain and/or itch) in five 
  
45 
separate trials. To be scored as present, the sensation has to be experienced in more than 
1 out of the 5 trials. 
 
4.4.1.2 Assessment of Pin-Prick Induced Sensation 
Pinprick stimuli were applied to the skin with a series of probes consisting of the 
following: 2 mL or 10 mL syringe barrels containing a free-floating sterile 27 gauge 
cannula above which rested one of the following weights: 1.0, 2.3, 3.7, 8.6, or 14.8 g. 
Each probe was laid down slowly and perpendicularly onto the skin surface in a manner 
that prevents insertion into the skin, and then held for 2 seconds. The subjects were asked 
to describe the quality and intensity of the evoked sensation. The intensities of itch and 
pain were reported separately by drawing a line on a 100mm length Visual Analogue 
Scale (VAS) with one end of this scale anchored as no sensation and the other end 
anchored as maximal sensation imaginable (Appendix VI). This procedure was repeated 
5 times with each load in the area of the skin. For reasons of hygiene and to eliminate 
cross-infection, fresh sterile needles and syringe barrels were used for each subject. 
 
4.4.1.3 Assessment of Thermal Induced Sensation (sensation of mildly painful and 
non-damaging heat as itch) 
A single thin metal rod (diameter of ~10mm) was preheated to 49 °C in a temperature-
controlled water bath and then sequentially applied perpendicularly to the skin and held 
for 10 seconds. This temperature with this short length of application was not enough to 
cause thermal damage to the skin. The subjects were asked to rate the intensities of the 
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evoked itch and pain on the VAS as described in the "pin-prick induced sensation". This 
procedure was performed once in the same area of skin for all other sensory tests. 
 
4.4.1.4 Assessment of Cowhage-Spicule Induced Sensation 
The spicules were inserted by rubbing in a circular fashion limited to an area of ~1.5 cm2 
for 40 seconds (Papoiu et al., 2011) and approximately 40 spicules were placed on the 
skin at each trial. Given the tiny size of the spicule, subjects could not feel the actual act 
of the insertion. Inserting the spicule did not cut the patient or cause any damage to the 
skin. After inserting the spicule and every 30 seconds afterwards, the subjects were asked 
to describe the sensation they felt and record its maximum intensity on a labeled 
magnitude scale using a computer software program specifically written and adapted to 
this purpose. This computer program, created for the laboratory of Dr. LaMotte, was 
graciously shared with us as a courtesy.  
 
This computer program uses a labeled magnitude scale (LaMotte et al., 2009; Sikand et 
al., 2009). The subjects rate the perceived intensity of itch, burning and pricking/tingling 
using the general version of the Labeled Magnitude Scale (gLMS). This scale presents 
subjects with intensity markers including “no sensation”, “barely detectable”, “weak”, 
“moderate”, “strong”, “very strong” positioned at appropriate locations along the scale in 
relation to the “strongest imaginable sensation of any kind”, that was placed at the top. 
Ratings of each of the three sensory qualities were obtained every 30 s from the moment 
of spicule insertion until 20 min elapsed or until each quality was judged as "barely 
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detectable" 3 times in a row. No subjects in either group exceeded the 20-minute mark. 
The subjects judged the magnitude of each quality by using a computer mouse to move 
the cursor along the scale as presented on a video screen. Each subject received prior 
training during which they used the gLMS to judge the magnitude of familiar sensory 
experiences such as the “sting of a bee” and the “itch from a mosquito bite.” Any 
sensation rated below barely detectable on the scale was considered as “zero”. These 
instructions on how to use the computer to assess the itch are included in the text for the 
description of different sensations (Appendix V). The generalized scale on the computer 
appears as a vertical line 230 mm high. Considering the scale to be 100 units, the labels 
were placed no sensation, 0; at barely detectable, 1.4; weak, 6; moderate, 17; strong, 
34.7; very strong, 52.5; strongest imaginable sensation of any kind, 100. 
 
This computer program only stores responses entered by the user with no other associated 
information. The files containing these data were named with the subject's unique study 
ID and the date of acquisition. 
 
4.4.2 Biopsies 
The principal investigator (Deon Wolpowitz, MD, Ph.D.) performed a single 6mm punch 
biopsy procedure at the area where the sensitization tests were performed, according to 
standard of care practices. Biopsy sites were closed using non-absorbing sutures. Sutures 
were removed 2 weeks after the biopsy either at the outpatient clinic of the Dermatology 
Department or at DaVita Dialysis Center. Wound care instructions were discussed with 
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the subject, including daily application of a Band-Aid to the dry wound covered with 
plain petroleum jelly until it healed. Specimens were labeled with the date of visit and 
subjects/control's unique identifying code only. Left over tissue was saved in a repository 
with informed, written consent, otherwise the left over tissue was discarded after the 
study.  
 
4.5 Immunohistochemistry 
Skin tissue were placed directly into Periodate-lysine-paraformaldehyde (PLP) fixative 
for 24 hrs, then cryoprotected with 20% sucrose in 0.1M Sorrenson’s buffer, frozen with 
dry ice, then cut into 50μm sections with a cryostat. Skin tissue sections were then 
processed for multi-labeled immunofluorescence localization of nerves with the 
following combinations of primary antibodies applied in the sequential order listed:  
rabbit anti-NPPB, guinea pig anti-Protein Gene Product (PGP)9.5, then mouse anti-
CGRP; rabbit anti-NPPB, mouse anti-PGP9.5, then guinea pig anti-SP. Rabbit anti-
TRPV-1 was used for single-label immunofluorescence. Sequential fluorophore-
conjugated tyramide detection (Perkin Elmer, Waltham, MA/Invitrogen, Grand Island, 
NY) was accomplished by horse-radish peroxidase (hrp) inactivation with hydrogen 
peroxide incubation. For each antibody combination, appropriate negative controls 
omitting each primary antibody were carried out, confirming complete inactivation of the 
first hrp-conjugate as well as absence of cross-reactivity of the secondary antibodies.  
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4.5.1 Primary Antibodies 
Primary antibodies were as follows: guinea pig anti-substance P (SP, 1:6000; Neuromics, 
Edina, MN), mouse anti-calcitonin-gene-related peptide (CGRP, 1:250; Enzo Life 
Sciences), mouse anti-protein gene product 9.5 (PGP9.5, 1:1500; Abcam, Cambridge, 
MA), guinea pig anti-protein gene product 9.5 (PGP9.5, 1:750, Neuromics), rabbit anti-
NPPB antibody (NPPB, 1:750; Proteintech, Chicago, IL), and rabbit anti-TRPV-1 
(TRPV-1, 1:175, Pierce, Rockford, IL). Secondary antibodies conjugated to hrp, were 
donkey anti-mouse, donkey anti-guinea pig, which were obtained from Jackson 
Immunoresearch (West Grove, PA) and vector rabbit from ImmPRESS reagents (Vector 
Labs, Burlingame, CA).    
 
4.6 Nerve Length Quantitation 
All skin specimens derived from the 6mm punch biopsy. Three consecutive sections from 
each specimen, corresponding to the central, largest portion of the biopsy, were used to 
represent each subject in nerve length quantitation. For each 50 µm section, fluorescence 
images were acquired at 4 μm intervals throughout the depth of the specimen using a 20x 
lens (Z-series), separately for each fluorescent signal, using the Nikon deconvolution 
wide-field epifluorescence system. To quantify nerve lengths in these sections, Nikon 
software was used to image two pieces of each section in consecutive, non-overlapping 
20x fields. In the triple-labeled specimens, each piece was constructed by tiling 3X2 Z-
stacks into one composite Z-stack. Each 3X2 tiling Z-stack gave an average linear 
epidermal length of 1.3mm, so two 3X2 tiling Z-stacks with average 2.7mm linear 
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epidermal length were chosen to represent the whole section, which was comparable to a 
3mm biopsy. Each 3X2 tiling field was chosen where the most NPPB-staining nerves 
were visually seen in the triple-label staining. In the single-label immunofluorescence 
with rabbit anti-TRPV-1, each piece was constructed with 4X2 tiling Z-stack. Each 4X2 
tiling Z-stack gave an average linear epidermal length of at least 1.6mm. Two 4X2 Z-
stacks with linear epidermal length 3.2mm were chosen to represent the section. Location 
of the two pieces in one section applies to the other two sections from the same specimen. 
In all cases, the imaging field had at its most rostral edge, the stratum corneum. Thus, 
images contained the entire epidermis, papillary dermis, at least the superficial reticular 
dermis (including a depth of at least 300 μm beneath the dermal-epidermal junction). 
Three-dimensional reconstruction of each Z-series was produced using Image J software 
(NIH) with the micro-manager plug-in. Each Z-series was then projected into a single in-
focus image (Z-projection), and nerve fibers within the papillary dermis or epidermis, 
corresponding to single, double, or triple-labeled fibers were identified by manual 
comparison of the respective fluorescent Z-series. Neuron J software was used to 
manually trace nerve fibers in each Z-projection as well as to quantitate the resulting 
nerve length (Hirai et al., 2000; Meijering et al., 2004 ; Timmes et al., 2013). 
 
4.7 Intraepidermal Nerve Fiber (IENF) Density  
For IENF quantitation, 3 consecutive sections from each specimen, corresponding to the 
central, largest portion of the biopsy, were stained with TRPV-1. Intraepidermal nerve 
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fiber densities were determined under epifluorescence microscope (Nikon Eclipse E400, 
TRITC channel) using standard procedures, counting only branches that cross the 
dermoepidermal junction (DEJ) at 40x (objective) and 10x (eyepiece) (Lauria et al., 
2005). Only the pieces that were imaged for nerve length quantitation were used for 
IENF counting. Image J was used to measure the linear length of epidermis.  
 
4.8 Data Analysis 
1) Duration of Hemodialysis: mean and standard deviation (SD) were used to represent 
the cases/controls group. Student's t-test with equal variances was used to compare cases 
and controls, to compare female subjects in cases and controls and to compare male 
subjects in cases and controls. 
 
2) Three VAS scores: median and 25–75% quantiles were used to represent the 
cases/controls group. Non-parametric Wilcoxon rank-sum test was used to compare cases 
and controls, to compare female subjects in cases and controls, to compare male subjects 
in cases and controls, to compare female vs. male subjects within cases, and to compare 
female vs. male subjects within controls.  
 
3) QoL questionnaire: scores were enumerated as indicated in the QoL questionnaire (1 = 
never, 2 = rarely, 3 = sometimes, 4 = often, 5 = all the time), then it was categorized into 
total symptoms score, total functioning score and total emotions score as follows. Median 
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and 25–75% quantiles were used to represent the cases/controls group. Non-parametric 
Wilcoxon rank-sum test was used to compare cases and controls, to compare female 
subjects in cases and controls, to compare male subjects in cases and controls, to compare 
female vs. male subjects within cases, and to compare female vs. male subjects within 
controls. 
Total symptoms score = average of responses (Question: 1–6) 
Total functioning score = average of responses (Question: 7–16) 
Total emotions score = average of responses (Question: 17–22) 
 
4) Assessment of brush-stroke induced sensation: more than once rating positive itch or 
pain out of five rounds was required to qualify that subject as having itch or pain induced 
from cotton swab rubbing, and was scored as 1. Zero or a single rating positive for itch or 
pain was deemed as a negative sensation for itch or pain, and was scored as 0. Median 
and 25–75% quantiles were used to represent the cases/controls group. Non-parametric 
Wilcoxon rank-sum test was used to compare cases and controls.  
 
5) Pin-prick induced sensation: for each subject the mean of five ratings of either itch or 
pain was used to represent the individual. Median and 25–75% quantiles were used to 
represent cases/controls group. Non-parametric Wilcoxon rank-sum test was used to 
compare cases and controls.  
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6) Thermal-induced sensation: Median and 25–75% quantiles were used to represent 
cases/controls group. Non-parametric Wilcoxon rank-sum test was used to compare cases 
and controls.  
 
7) Assessment of cowhage-spicule induced sensation: From the ratings of each sensory 
quality for each subject, the values of the following parameters were obtained: the peak 
magnitude of the ratings, the time from the onset of sensation to the peak, the duration of 
sensation (time between onset of sensation and the first of the three consecutive ratings of 
zero) and the area under the curve (AUC). Median and 25–75% quantiles were used to 
represent case/control groups. Non-parametric Wilcoxon rank-sum test was used to 
compare cases and controls. Cowhage data from subject 1 was excluded for analysis 
because this subject could not be adequately trained either to understand the different 
cutaneous sensations or how to use the computer software to rate them. Accordingly, 
subject 1 was excluded from correlation analysis involving cowhage spicule-induced 
sensations. Because subject 1 could adequately understand how to rate itch using the 
VAS scales, quantitation of nerves from subject 1 was included for comparison of nerve 
measurements between cases and controls and correlation studies with a VAS score. 
 
8) IENF density: IENF number was determined in three consecutive sections and the sum 
divided by the total linear length of epidermis in these three sections. Mean and standard 
deviation (SD) were used to represent case and control groups. Two-tailed Student's t-test 
was used to compare cases and controls. 
  
54 
9) Nerve Length Quantitation: Two areas of each tissue section were selected depending 
on the antibodies used. In triple immunohistochemical stains that included NPPB, the 
areas visually bearing the most NPPB nerves were selected. For the TRPV-1 
immunohistochemical stain, bilateral edges of each piece were selected. The values from 
each area were combined to obtain a single representative value for that entire tissue 
section.  Each section was treated as one data point for the individual subject. For each 
tissue section, epidermis length was measured using Image J software. Epidermis to total 
epidermal and papillary dermal ratio of TRPV-1 nerve length (%Epi) was calculated as 
the total nerve length of TRPV-1 in epidermis divided by the sum of the total nerve 
length of TRPV-1 in both the epidermis and papillary dermis. Papillary dermis to total 
epidermal and papillary dermal ratio of TRPV-1 nerve length (%PD) was calculated as 
the total nerve length of TRPV-1 in the papillary dermis divided by the total nerve length 
of TRPV-1 in both the epidermis and papillary dermis. Intraepidermal TRPV-1 nerve 
length (IENL)/mm epidermis was calculated as the total nerve length of TRPV-1 in 
epidermis divided by the linear length of epidermis as determined by the linear length of 
the stratum corneum. Papillary dermal TRPV-1 nerve length (PDNL)/mm epidermis was 
calculated as the total nerve length of TRPV-1 in papillary dermis divided by the linear 
length of epidermis as determined by the linear length of the stratum corneum. Mean and 
standard deviation (SD) were used to represent case and control groups. Student's t-test 
with unequal variances was used to compare cases and controls in %Epi, %PD, 
IENL/mm epidermis and PDNL/mm epidermis.  
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For calculation of ratio of CGRP nerve length to total papillary dermal (pd)-PGP9.5 
nerve length (%PD-CGRP(+)), ratio of SP nerve length to total pd-PGP9.5 nerve length 
(%PD-SP(+)), ratio of NPPB nerve length to total pd-PGP9.5 nerve length (%PD-
NPPB(+)), ratio of CGRP(+)/NPPB(-) nerve length to total pd-PGP9.5 nerve length 
(%PD-CGRP(+)/NPPB(-)), ratio of CGRP(+)/NPPB(+) nerve length to total pd-PGP9.5 
nerve length(%PD-CGRP(+)/NPPB(+)), ratio of CGRP(-)/NPPB(+) nerve length to total 
pd-PGP9.5 nerve length(%PD-CGRP(-)/NPPB(+)), ratio of SP(+)/NPPB(-) nerve length 
to total pd-PGP9.5 nerve length(%PD-SP(+)/NPPB(-)), ratio of SP(+)/NPPB(+) nerve 
length to total pd-PGP9.5 nerve length(%PD-SP(+)/NPPB(+)), and ratio of SP(-
)/NPPB(+) nerve length to total pd-PGP9.5 nerve length(%PD-SP(-)/NPPB(+)), 
individual nerve length with each specific marker was divided by total PGP9.5 nerve 
length in the papillary dermis. Median and 25–75% quantiles were used to represent case 
and control groups. Non-parametric Wilcoxon rank-sum test was used to compare cases 
and controls. 
 
In subgroup quantification: For each tissue section from each tissue specimen, the “% of 
(marker A) nerve length that is also positive for (marker B)” was calculated as the total 
amount of a nerve length in that entire tissue section that co-expressed (markers A and B) 
divided by the total amount of nerve length in the papillary dermis in that entire tissue 
section expressing (marker A). %CGRP that is NPPB(+), %CGRP that is NPPB(-), 
%NPPB that is CGRP(+), %NPPB that is CGRP(-), %NPPB that is SP(+), %NPPB that 
is SP(-), %SP that is NPPB(+) and %SP that is NPPB(-) were measured. Median and 25–
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75% quantiles were used to represent case and control groups. Non-parametric Wilcoxon 
rank-sum test was used to compare cases and controls. 
 
10) Correlation analysis: the distribution of the Spearman rank correlation coefficient 
under the null hypothesis was computed through permutation test (10,000 permutations 
per variable) using R statistical software. Correlation analysis was used to test 
relationship between two variables with the outcome defined as the correlation 
coefficient(CC). CC was a value between -1 to +1 and shows if changes in one item will 
result in changes in the other item. For correlations involving nerve measurements, the 
total respective nerve lengths, obtained from all tissue sections from a given biopsy 
specimen, were aggregated and then used to generate a single cumulative respective 
nerve length percentage for the entire tissue specimen. There were four sets of correlation 
analyses performed: 1) nerve measurements and cowhage-induced itch data; 2) nerve 
measurements and VAS score-average itch preceding week; 3) duration of hemodialysis 
and VAS- average itch preceding week; and 4) duration of hemodialysis and cowhage-
induced itch data.  
 
11) Software: JMPPro software (JMP, Cary, NC) was used to identify medians and 
quantiles; mean and standard deviation; and to perform non-parametric Wilcoxon rank-
sum test or Student's t-test.  
 
12) P value: P value <0.05 for Wilcoxon rank-sum test, two-tailed Student's t-test and 
correlation was defined as significant. 
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CHAPTER 5. FINDINGS 
 
5.1 Demographics of Subjects (Table 5-1) 
12 cases and 13 controls were recruited. There were 6 females and 6 males in the case 
group. There were 7 females and 6 males in the control group. 9 out of 12 cases were 
African American/Hispanic and 3 out of 12 cases were Caucasian. 10 out of 13 controls 
were African-American/Hispanic, 3 out of 13 controls were Caucasian. The ratio of 
African-American/Hispanic to Caucasian subjects in the cases and controls were 
balanced (p=1.0). The predominantly African-American population in our study resulted 
from the skewed African-American population at DaVita Dialysis Center Boston. No 
significant differences existed in age between cases and controls, including when 
subgrouped by sex (Table 4-1). The median age of cases vs. controls was 55 years (25–75% 
quantiles: 45.75–70.75) vs. 59 years (51–72). In the group of males, the median age of 
cases vs. controls was 55 years (41.5–71.25) vs. 55 years (45–73.5). In the group of 
females, the median age of cases vs. controls was 59 years (47.25–72.25) vs. 67 years 
(51.00–71.00). There was no difference in hemodialysis duration between cases and 
controls, even when sub-grouped by sex. Moreover, within cases or controls group, there 
was also no difference of hemodialysis duration between female and male (cases: p=0.52; 
controls: p=0.60), consistent with the literature that uremic pruritus is independent of 
dialysis duration (Bernhard, 1994). 
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Table 5-1. Demographics of Subjects  
 
Cases Controls P value 
Total 12 13 1.00 
Males 6 6 1.00 
Females 6 7 1.00 
Black/Hispanics 9 10 1.00 
White 3 3 1.00 
Age, all subject (year) (median, 
25%–75%) 55.00 (45.75–70.75) 59.00 (51.00–72.00) 0.67 
Age, males 55.00 (41.50–71.25) 55.00 (45.00–73.50) 0.86 
Age, females 59.00 (47.25–72.25) 67.00 (51.00–71.00) 0.71 
Hemodialysis Duration (year) 
(mean±SD*) 3.73 ± 2.18 2.73 ± 2.23 0.28 
Hemodialysis Duration, males 
(year) 4.15 ± 1.85 3.09 ± 2.59 0.44 
Hemodialysis Duration, females 
(year) 3.23 ± 2.65 2.41 ±  2.03 0.55 
*SD: Standard Deviation  
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5.2 Itch Characterization (Table 5-2, 5-3) 
Three VAS scores were obtained to initiate the study visit: average itch for the preceding 
week, worst itch for the preceding week, and itch on the day of the study visit. There 
were no differences in VAS scores between females and males. VAS scores of cases, for 
all three measures, were significantly higher than those of controls. These data confirm 
that we have recruited two distinct populations of end-stage renal disease (ESRD) 
subjects: one with and one without pruritus. All cases reported itch involving the trunk 
area, especially the back, while some reported itch also involving the face and shoulders. 
Other areas with pruritus in individual subjects included, but were not limited to, the arms 
and legs.   
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Table 5-2. Itch Characterization (median, 25%–75% quantiles) 
   Cases Controls P value 
VAS, day of visit  41.50 (33.75–69.00) 0 (0–0.50) <0.0001 
VAS, average itch preceding week  78.00 (64.25–85.75) 0 (0–5.00) <0.0001 
VAS, worst itch preceding week  85.50 (73.00–93.75) 0 (0–3.00) <0.0001 
VAS, day of visit—female  66.00 (34.50–72.75) 0 (0–0) 0.002 
VAS, average itch preceding week—
female  
80.00 (63.25–
96.25) 0 (0–0) 0.002 
VAS, worst itch preceding week— female  87.00 (67.50–91.25) 0 (0–0) 0.002 
VAS, day of visit—male  40.50 (31.25–54.00) 0 (0–5.00) 0.004 
VAS, average itch preceding week—male  78.00 (60.75–85.25) 
3.50 (0–
15.25) 0.005 
VAS, worst itch preceding week—male  84.00 (75.00–98.50) 
2.00 (0–
22.25) 0.005 
VAS: Visual Analogue Scale 
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Table 5-3. Itch Characterization by Sex (median, 25%–75% quantiles) 
   Female Male P value 
VAS, day of visit—controls  0 (0–0) 0 (0–5.00) 0.50 
VAS, average itch preceding 
week—controls  0 (0–0) 3.50 (0–15.25) 0.06 
VAS, worse itch preceding 
week—controls  0 (0–0) 2.00 (0–22.25) 0.07 
VAS, day of visit— cases  66.00 (34.50–72.75) 40.50 (31.25–54.00) 0.47 
VAS, average itch preceding 
week—cases  80.00 (63.25–96.25) 78.00 (60.75–85.25) 0.75 
VAS, worse itch preceding 
week—cases  87.00 (67.25–91.25) 84.00 (75.00–98.50) 0.81 
VAS: Visual Analogue Scale 
 
5.3 Itchy QoL Frequency Questionnaire (Table 5-4, 5-5)  
Cases exhibited higher scores compared to controls in total symptoms score (3.00 vs. 
1.00), total functioning score (3.40 vs. 1.00) and total emotions score (2.59 vs. 1.00), 
regardless of sex. These data confirm that the itchy subjects experienced clinically 
meaningful pruritus that adversely affected their quality of life. In the cases, the ratings 
for all three were comparable to ratings for patients with pruritus from dermatitis, 
urticaria, and idiopathic causes (Desai et al., 2008)  
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Table 5-4. Itchy QoL Frequency Questionnaire (median, 25%–75% quantiles) 
 
Cases Controls P value 
Itchy QoL total symptoms score 3.00 (2.54–3.42) 1.00 (1.00–1.00) <0.0001 
Itchy QoL total functioning score 3.40 (2.88–3.88) 1.00 (1.00–1.00) <0.0001 
Itchy QoL total emotions score 2.59 (1.87–3.67) 1.00 (1.00–1.00) <0.0001 
Itchy QoL total symptoms score—female 3.00 (2.83–3.75) 1.00 (1.00–1.17) 0.002 
Itchy QoL total functioning score—female 3.45 (3.33–4.03) 1.00 (1.00–1.00) 0.002 
Itchy QoL total emotions score—female 3.50 (1.96–4.29) 1.00 (1.00–1.00) 0.002 
Itchy QoL total symptoms score—male 2.75 (2.46–3.54) 1.00 (1.00–1.00) 0.003 
Itchy QoL total functioning score—male 3.00 (2.25–3.60) 1.00 (1.00–1.00) 0.003 
Itchy QoL total emotions score—male 2.42 (1.67–2.92) 1.00 (1.00–1.00) 0.003 
QoL: Quality of Life 
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Table 5-5. Itchy QoL Frequency Questionnaire by Sex (median, 25%–75% 
quantiles) 
 
Female Male P value 
Itchy QoL total symptoms score—controls 1.00 (1.00–1.17) 1.00 (1.00–1.00) 0.21 
Itchy QoL total functioning score—controls 1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.44 
Itchy QoL total emotions score—controls 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1 
Itchy QoL total symptoms score—cases 3.00 (2.83–3.75) 2.75 (2.46–3.54) 0.52 
Itchy QoL total functioning score—cases  3.45(3.33–4.03) 3.00 (2.25–3.60) 0.17 
Itchy QoL total emotions score—cases 3.50 (1.96–4.29) 2.42 (1.67–2.92) 0.20 
QoL: Quality of Life 
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5.4 Tests for Sensory Sensitization 
5.4.1 Brush-Stroke Induced Sensation (Table 5-6) 
Brush-stroke sensation was induced by gently stroking with a cotton swab. Alloknesis 
(the sensation of itch induced by normally non-itchy mechanical stimuli) from this brush 
stroke was absent in 75% (9 out of 12) of cases and was absent in 92.3% (12 out of 13) of 
controls. Allodynia is the inappropriate perception of pain from non-painful stimuli. 
Brush-stroke induced allodynia was absent in cases and controls. There was no 
significant difference between cases and controls in regard to the presence or absence of 
either alloknesis or allodynia.  
 
Table 5-6. Brush-Stroke Induced Sensation (median, 25%–75% quantiles) 
  Cases Controls P value 
cotton swab rubbing—itch (alloknesis) 0 (0–0.75) 0 (0–0) 0.27 
cotton swab rubbing—pain (allodynia) 0 (0–0) 0 (0–0) 1.00 
 
5.4.2 Pin-Prick Induced Sensation 
Tests for pain and/or itch induced by a pin-prick carrying a load of 1.0 gm, 2.3 gm, 8.6 
gm and 14.8 gm were performed.    
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5.4.2.1 Pin-Prick Induced Pain (Punctate Hyperalgesia) 
Cases reported more pin-prick induced pain than controls. Pin-prick carrying a load of 
1.0 gm induced pain in 4/12 cases, 0/13 controls. Pin-prick carrying a load of 2.3 gm 
induced pain in 4/12 cases, 1/13 controls. Pin-prick carrying a load of 8.6 gm induced 
pain in 4/12 cases, 1/13 controls. Pin-prick carrying a load of 14.8 gm induced pain in 
5/12 cases, 2/13 controls. Nevertheless, for all tested weights, only the 1.0 gm load 
showed a statistically significant difference in the amount of pinprick-induced pain 
between cases and controls (Table 5-7). Also, the low intensity of pain experienced by 
cases (median, 2.5 out of 100, Table 5-7) was of questionable biologic relevance. Thus, 
punctate hyperalgesia (enhanced pin-prick induced pain) was absent in cases. For either 
cases or controls, there were no statistically significant differences in pain sensation with 
increasing weight loads (Table 5-8). These findings indicate cases and controls exhibit 
hypoalgesia to pin-prick pain. This interpretation is not favored given that subjects 
experienced pain from the local anesthetic injection. Instead, these results are interpreted 
as experimental error secondary to the weights selected not being heavy enough to induce 
meaningful pin-prick pain. The weights may have been insufficient either because of the 
increased thickness of back skin and/or because these subjects have an unusually high 
pain tolerance from being regularly subjected to more intense mechanical noxious stimuli 
(i.e., dialysis with wide-bore needles).  
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Table 5-7. Pin-Prick Induced Pain (Punctate Hyperalgesia) (median, 25%–75% 
quantiles) 
Weights (gm) Cases–-pain Controls–-pain P value 
1.00 2.50 (0–10.30) 0 (0–0.10) 0.03 
2.30 0 (0–17.10) 0 (0–0.50) 0.31 
8.60 0 (0–21.10) 0 (0–1.00) 0.34 
14.80 3.50 (0–29.90) 0 (0–2.90) 0.17 
 
Table 5-8. Pin-Prick Induced Pain Comparison of Different Weight Loads  
Pain   Cases Controls 
Level Level P value P value 
weight 1.00 weight 14.80 0.42 0.18 
weight 2.30 weight 8.40 0.90 0.88 
weight 1.00 weight 8.40 0.90 0.60 
weight 1.00 weight 2.30 0.67 0.67 
weight 14.80 weight 8.40 0.41 0.33 
weight 14.80 weight 2.30 0.26 0.29 
 
5.4.2.2 Pin-Prick Induced Itch (Punctate Hyperknesis) 
Cases experienced significantly more pin-prick induced itch versus controls (Table 5-9). 
However, the biological significance of this difference is uncertain give the relatively low 
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level of itch induced (VAS range, 1.4 to 3.1 out of 100) and absence of significant 
differences in itch-induction for different weights within cases or controls (Table 5-10).   
 
Table 5-9. Pin-Prick Induced Itch (Punctate Hyperknesis) (median, 25%–75% 
quantiles) 
Weights (gm) Cases–-itch Controls–-itch P value 
1.00 1.40 (0–17.15) 0 (0–0) 0.03 
2.30 1.40 (0–34.40) 0 (0–0) 0.02 
8.40 3.10 (0–39.35) 0 (0–0) 0.04 
14.80 1.90 (0–40.30) 0 (0–0) 0.005 
 
Table 5-10. Pin-Prick Induced Itch Comparison of Different Weight Loads  
Itch   Cases Controls 
Level Level P value P value 
weight 1.00 weight 14.80 0.78 0.36 
weight 2.30 weight 8.40 0.88 0.64 
weight 1.00 weight 8.40 0.64 0.64 
weight 1.00 weight 2.30 0.85 1.00 
weight 14.80 weight 8.40 0.93 0.17 
weight 14.80 weight 2.30 1.00 0.36 
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Punctate hyperalgesia and punctate hyperknesis are mediated by Aδ-fibers (Schmelz 
2006). Immunohistochemical staining with an antibody to neurofilament (NF)-200 to 
identify Aδ-fibers was not performed.  
 
5.4.3 Thermal Induced Sensation 
Thermal-induced sensations of heat pain and/or itch were not technically possible in all 
subjects. A metal rod was preheated to 49 °C in a water bath then applied to the skin for 
10 sec with one cross-section end touching the skin. Pain was induced in only 4 subjects 
in total, 2 cases and 2 controls. Itch was induced in 3 cases and 1 control. There were no 
statistically significant differences between cases and controls for itch or pain sensation 
(Table 5-11). We attribute these results to rapid dissipation of heat from the metal rod, 
and its subsequent inability to preserve the desired temperature for 10 seconds outside of 
the water bath. Thus, heat pain or heat-induced itch could not be meaningfully assessed in 
cases or controls.   
 
Table 5-11. Thermal Induced Sensation (median, 25%–75% quantile) 
  Cases Controls P value 
Heat--itch 0 (0–1.50) 0 (0–0) 0.29 
Heat--pain 0 (0–1) 0 (0–0) 0.74 
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5.4.4 Cowhage-Spicule Induced Sensation (Table 5-12) 
Cowhage spicules induce cutaneous sensations via the histamine-independent, protease-
dependent pathway (Steinhoff et al., 2003). Cowhage produces predominantly itch with 
lesser components of pricking/tingling and burning (LaMotte et al., 2009). The 
dimensions and intensities of cowhage-spicule induced itch were measured to evaluate 
for sensitization of this histamine-independent itch pathway. Our data show that area 
under the curve (AUC) for itching (-itching) and peak perceived intensity of itch (peak 
itch) were significantly higher in cases compared to controls (Table 5-12). There was no 
statistical difference in prickling/tingling or burning between cases or controls. 
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Table 5-12. Cowhage-Spicule Induced Sensation (median, 25%–75% quantile) 
   Cases Controls P value 
peak itch  53.60 (53.30–78.80) 34.20 (20.90–55.60) 0.02 
AUC* itching  175.40 (101.00–252.20) 42.40 (24.00–160.70) 0.04 
time to peak itch  2.50 (1.00–3.00) 1.00 (0.50–1.50) 0.06 
total time itch  7.00 (5.50–9.50) 4.00 (3.00–7.25) 0.11 
peak burning 70.20 (53.10–91.00) 52.80 (11.50–76.70) 0.17 
AUC burning  183.80 (80.30–266.40) 38.80 (3.30–156.90) 0.16 
time to peak burning  1.00 (0.50–4.00) 0.50 (0.50–0.80) 0.05 
total time burning 5.50 (2.00–8.00) 2.50 (1.80–3.50) 0.15 
peak pricking/tingling  52.90 (18.20–59.10) 17.00 (0.30–66.40) 0.26 
AUC pricking/tingling  105.80 (27.40–201.00) 12.70 (0.30–165.00) 0.27 
time to peak 
pricking/tingling  1.50 (1.00–2.50) 1.00 (0.30–1.50) 0.10 
total time pricking/tingling  5.50 (2.50–6.50) 2.50 (0.80–4.50) 0.10 
*AUC, Area Under the Curve 
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Table 5-13. Comparison of Cowhage-Spicule Induced Sensation within Cases or 
Controls  
    Cases Controls 
Level Level P value P value 
AUC* itching AUC burning 0.69 0.63 
AUC pricking/tingling AUC burning 0.32 0.49 
AUC pricking/ting AUC itching 0.15 0.27 
*AUC, Area Under the Curve 
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5.5 Analysis of Epidermal and Papillary Dermal Innervations (Table 5-13) 
5.5.1 Intraepidermal Nerve Fiber (IENF) Density 
Cases showed an IENF density of 13.3±7.9/mm, and controls showed an IENF density of 
17.7±3.8/mm. IENF density was not statistically significantly different between cases and 
controls (p=0.10). 
  
5.5.2 Nerve Length Quantitation 
5.5.2.1 Description of Nerve Innervation in Subjects' Skin 
In all subjects, CGRP, NPPB and SP positive nerves reside in the dermis, predominantly 
the papillary dermis. None of the nerves staining with these three peptidergic markers 
crossed the dermal-epidermal junction and into the epidermis. 
 
In controls, of the three peptidergic nerve markers, calcitonin gene related peptide (CGRP) 
comprised the highest percentage of nerves in the papillary dermis (median, 28%). 
Substance P (SP) comprised ~3% and natriuetic polypeptide precursor B (NPPB), ~1.8% 
of papillary dermal nerves. In cases, CGRP still comprised the highest percentage in the 
papillary dermis (median, 8%). SP comprised about 3% and NPPB comprised about 0.8% 
of papillary dermal nerves.  
 
In controls, more than 80% of NPPB(+) nerves were CGRP(+). In cases, NPPB(+) nerves 
rarely co-stained with CGRP(+) nerves (% PD-NPPB(+)/CGRP(+): median (25%–75% 
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quantiles), 0% (0–0.8%)). In all subjects, NPPB(+) nerves only rarely co-expressed SP(+) 
(% PD-NPPB(+)/SP(+): median (25%–75% quantiles), cases 0%(0–0), controls 0% (0–
0.1%)). In controls, the majority of CGRP(+) nerves were NPPB(-) (%CGRP that is 
NPPB(-): median, 87.9%). In cases, almost all CGRP(+) nerves were NPPB(-) (median, 
100%). In all subjects, almost all SP(+) nerves were also NPPB(-) (median, 100%).  
 
5.5.2.2 Comparison of Epidermal Innervation in Cases and Controls 
In both cases and controls, there was no statistical difference in %Epi between cases 
(24.80%) and controls (25.30%). In controls, IENL/mm was 963.0 ± 294.8/mm; in cases, 
IENL/mm was 854.1 ± 572.5/mm. There was no statistical difference in IENL/mm 
between cases and controls. Taken together, there was no difference in epidermal 
innervation in cases and controls. 
 
5.5.2.3 Comparison of Dermal Innervation in Cases and Controls 
Consistent with no difference in %Epi in cases and controls, there was no difference 
in %PD in cases and controls, with about 75% of total nerves residing in the papillary 
dermis. However, PDNL/mm was 20% lower in cases compared to controls (p=0.0009). 
In controls, PDNL/mm was 2952.60 ± 855.90/mm; in cases, PDNL/mm was 2241.60 ± 
917.14/mm. Consistent with the loss of papillary dermal nerves, %PD-CGRP(+) was also 
reduced in cases versus controls (p<0.0001), from 28% in controls to 7% in cases 
(corresponding to an absolute reduction of 20% of the entire nerve population and a 
relative 75% reduction in the value of %PD-CGRP(+) nerves). We therefore attribute the 
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reduction in PDNL/mm in cases to a decrease in number of CGRP nerves in the papillary 
dermis. The reason behind the discrepancy in %PD and PDNL/mm was the epidermal 
nerve length was taken into account in calculating %PD. Given the variability in 
epidermal nerve length, we cannot exclude that with a larger sample size, %PD could 
become statistically significant.  
 
The population of CGRP(+) nerves in the papillary dermis was further divided into 
CGRP(+)/NPPB(+) nerves and CGRP(+)/NPPB(-) nerves. When each one is normalized 
to the total papillary dermal PGP9.5 nerve length, both percentages were significantly 
reduced in cases when compared to (p =0.0003, p <0.0001, respectively). Furthermore, 
the ratio of CGRP(+)/NPPB(+) nerves to the total CGRP(+) nerve population, expressed 
as %CGRP that is NPPB(+), was statistically significantly reduced (cases vs. controls 
(median): 0% vs. 12.10%; p=0.03).  
 
In cases, %PD-NPPB(+) was also reduced, (cases vs. controls: 0.8% (0%–2.9%) vs. 1.8% 
(0.2%–5.2%); p=0.01). NPPB(+) nerves in the papillary dermis were further divided into 
NPPB(+)/CGRP(+) and NPPB(+)/CGRP(-) nerves. There was a statistically significant 
reduction of NPPB(+)/CGRP(+) nerves, with preservation of NPPB(+)/CGRP(-) nerves. 
The reduction of NPPB(+)/CGRP(+) nerves can be expressed in two ways. The first was 
by comparing NPPB(+)/CGRP(+) nerves to total papillary dermal nerves, expressed 
as %PD- NPPB(+)/CGRP(+) nerves, that was statistically significantly reduced in cases 
versus controls (p= 0.0003). The second was by comparing NPPB(+)/CGRP(+) nerves to 
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total papillary dermal NPPB(+) nerves, expressed as %PD-NPPB(+) that is CGRP(+), 
that was also significantly decreased in cases versus controls (p= 0.0002). Thus, we 
conclude that loss of papillary dermal NPPB nerves was attributable to the loss of 
papillary dermal CGRP nerves.  
 
There was no significant difference between cases and controls in regard to %PD-
SP(+), %PD-NPPB(-)/SP(+) and % PD-NPPB(+)/SP(+). Virtually no NPPB and SP co-
staining nerves were identified in the papillary dermis in both cases and controls. Thus, 
we conclude that there was no change in SP expression in the papillary dermal nerves in 
cases compared to controls. In accordance with the above results, %NPPB that was 
SP(+), %NPPB that was SP(-), %SP that was NPPB(+), and %SP that was NPPB(-), were 
unchanged in cases compared to controls. In conclusion, changes in the neuroanatomy of 
SP-expressing cutaneous nerves were of little importance in the pathophysiology of 
uremic pruritus.  
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Table 5-14. Analysis of Epidermal and Papillary Dermal Innervation (median, 
25%–75% quantiles) 
 
Cases Controls P value 
IENF*§ 13.30 ± 7.90 17.70 ± 3.80 0.10 
IENL/mm*§ 854.10 ± 572.50 963.00 ± 294.80 0.31 
%Epi § 24.80 ± 11.30 25.30 ± 7.00 0.85 
PDNL*/mm§ 2241.60 ± 917.14 2952.60 ± 855.90 0.0009 
%PD*§ 75.20 ± 11.30 74.70 ± 7.00 0.85 
%PD-CGRP* (+)  7.20 (1.90–17.90) 28.10 (19.70–36.20) <0.0001 
%PD-SP* (+) 2.70 (0.80–4.70) 3.60 (2.00–5.90) 0.10 
%PD-NPPB* (+) 0.80 (0–2.90) 1.80 (0.20–5.20) 0.01 
%PD-NPPB(+)/CGRP(-)  0.60 (0–1.20) 0.40 (0–0.90) 0.30 
%PD-NPPB(-)/CGRP(+) 6.80 (1.70–16.60) 22.80 (12.50–31.40) <0.0001 
%PD-NPPB(+)/CGRP(+) 0 (0–0.80) 3.00 (0–8.20) 0.0003 
%PD-NPPB(+)/SP(-) 0.80 (0–1.60) 1.20 (0–3.40) 0.32 
%PD-NPPB(-)/SP(+) 2.10 (0.60–4.70) 3.30 (1.40–5.60) 0.15 
%PD-NPPB(+)/SP(+) 0 (0–0) 0 (0–0.10) 0.37 
%NPPB that is CGRP(-) 44.10 (0–100) 7.90 (0–24.90) 0.06 
%NPPB that is CGRP(+) 0 (0–50.70) 84.20 (0–97.80) 0.0002 
%CGRP that is NPPB(-) 100.00 (68.30–100.00) 87.90 (70.00–100.00) 0.16 
%CGRP that is NPPB(+) 0 (0–15.90) 12.10 (0–30.00) 0.03 
%NPPB that is SP(-) 81.50 (0–100.00) 89.90 (0–100.00) 0.88 
%NPPB that is SP(+) 0 (0–0) 0 (0–1.50) 0.44 
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%SP that is NPPB(-) 100.00 (69.60–100) 100.00 (83.20–100) 0.80 
%SP that is NPPB(+) 0 (0–0) 0 (0–2.50) 0.27 
§: mean±SD 
*IENF: intraepidermal nerve fiber 
  IENL/mm: Intraepidermal nerve length/mm epidermis 
  PDNL/mm: Papillary dermal nerve length/mm epidermis 
  PD: Papillary Dermis 
  CGRP: Calcitonin Gene Related Peptide 
  SP: Substance P 
  NPPB: Natriuretic Polypeptide Precursor B 
 
5.6 Correlation Analysis 
5.6.1 Correlation of Nerve Measurements and Cowhage-Spicule Induced Itch  
In cases, AUC itching correlated negatively with %PD-CGRP(+) (CC= -0.40, p=0.02) 
and %PD-NPPB(-)/CGRP(+) (CC= -0.43, p= 0.009) (Table 5-15). Peak itch was not 
significantly correlated with any nerve measurements statistically. These data suggest 
that loss of papillary dermal CGRP nerves may contribute to augmented cowhage itch by 
loss of an itch-inhibition signal.  
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Table 5-15. Correlation of Nerve Measurements and Cowhage-Spicule Induced Itch 
in Cases 
Cases CC*-AUC* itching 
P value-AUC 
itching 
CC-peak 
itch 
P value-
peak itch 
IENF* -0.04 0.41 -0.08 0.35 
IENL/mm* -0.18 0.20 -0.13 0.27 
%Epi  -0.23 0.14 -0.24 0.13 
PDNL/mm* 0.32 0.06 0.31 0.07 
%PD* 0.23 0.14 0.24 0.13 
%PD-CGRP* (+)  -0.40 0.02 -0.26 0.10 
%PD-SP* (+) 0.05 0.40 -0.29 0.08 
%PD-NPPB* (+) -0.12 0.30 -0.14 0.25 
%PD-NPPB(+)/CGRP(-)  0.003 0.46 -0.11 0.29 
%PD-NPPB(-)/CGRP(+) -0.43 0.0086 -0.28 0.09 
%PD-NPPB(+)/CGRP(+) -0.14 0.27 -0.09 0.33 
%PD-NPPB(+)/SP(-) -0.05 0.43 -0.22 0.15 
%PD-NPPB(-)/SP(+) 0.06 0.39 -0.22 0.15 
%PD-NPPB(+)/SP(+) -0.04 0.49 -0.34 0.05§ 
%NPPB that is CGRP(-) 0.15 0.23 0.05 0.41 
%NPPB that is CGRP(+) 0.11 0.29 0.13 0.27 
%CGRP that is NPPB(-) -0.10 0.30 0.19 0.18 
%CGRP that is NPPB(+) 0.10 0.30 -0.19 0.18 
%NPPB that is SP(-) 0.11 0.32 0.20 0.17 
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%NPPB that is SP(+) 0.34 0.06 0.11 0.30 
%SP that is NPPB(-) -0.09 0.31 0.14 0.26 
%SP that is NPPB(+) 0.09 0.31 -0.14 0.26 
§: the original P value is larger than 0.05 but is expressed as 0.05 due to rounding off to 
two decimal places.  
*CC: Correlation Coefficient 
  AUC: Area Under the Curve 
  IENF: intraepidermal nerve fiber 
  IENL/mm: Intraepidermal nerve length/mm epidermis 
  PDNL/mm: Papillary dermal nerve length/mm epidermis 
  PD: Papillary Dermis 
  CGRP: Calcitonin Gene Related Peptide 
  SP: Substance P 
  NPPB: Natriuretic Polypeptide Precursor B 
 
In controls, %PD-NPPB(+) (CC=0.42, p=0.017) and %PD-NPPB(+)/CGRP(+) (CC=0.45, 
P=0.01) both positively correlated with peak itch. These data suggest that in controls, 
PD-NPPB(+) nerves may mediate cowhage-induced itch. We observed a statistically 
significant correlation between the nerve measurement of SP and peak itch. Peak itch 
significantly negatively correlated with %PD-SP that is NPPB(-) but not with %PD-
SP(+). As there are virtually no SP(+)/NPPB(+) nerves, these two pieces of data 
contradict each other. We cannot exclude with a larger sample size, %PD-SP would have 
reached statistical significance. Nevertheless, with our current sample size, these data are 
inconclusive.  
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Table 5-16. Correlation of Nerve Measurements and Cowhage-Spicule Induced Itch 
in Controls 
Controls CC*-AUC* itching 
P value-AUC 
itching 
CC-peak 
itch 
P value-
peak itch 
IENF* -0.0005 0.48 0.28 0.09 
IENL*/mm 0.20 0.18 0.08 0.35 
%Epi  0.15 0.25 -0.05 0.40 
PDNL*/mm -0.04 0.43 0.15 0.23 
%PD* -0.15 0.25 0.05 0.40 
%PD-CGRP* (+)  0.07 0.36 -0.11 0.30 
%PD-SP* (+) -0.09 0.34 -0.28 0.09 
%PD-NPPB* (+) 0.28 0.10 0.42 0.02 
%PD-NPPB(+)/CGRP(-)  -0.11 0.34 -0.27 0.10 
%PD-NPPB(-)/CGRP(+) -0.05 0.43 -0.30 0.07 
%PD-NPPB(+)/CGRP(+) 0.30 0.09 0.45 0.01 
%PD-NPPB(+)/SP(-) -0.22 0.14 0.01 0.48 
%PD-NPPB(-)/SP(+) -0.24 0.12 -0.50 0.007 
%PD-NPPB(+)/SP(+) 0.35 0.06 0.49 0.003 
%NPPB that is CGRP(-) 0.13 0.27 0.03 0.44 
%NPPB that is CGRP(+) -0.13 0.27 -0.03 0.44 
%CGRP that is NPPB(-) -0.20 0.18 -0.38 0.03 
%CGRP that is NPPB(+) 0.20 0.18 0.38 0.03 
%NPPB that is SP(-) -0.57 0.003 -0.39 0.03 
%NPPB that is SP(+) 0.34 0.06 0.49 0.01 
%SP that is NPPB(-) -0.30 0.08 -0.49 0.005 
%SP that is NPPB(+) 0.30 0.08 0.49 0.005 
*CC: Correlation Coefficient 
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  AUC: Area Under the Curve 
  IENF: intraepidermal nerve fiber 
  IENL/mm: Intraepidermal nerve length/mm epidermis 
  PDNL/mm: Papillary dermal nerve length/mm epidermis 
  PD: Papillary Dermis 
  CGRP: Calcitonin Gene Related Peptide 
  SP: Substance P 
  NPPB: Natriuretic Polypeptide Precursor B 
 
5.6.2 Correlation of Nerve Measurements and VAS-Average Itch Preceding Week  
Controls had no pruritus, as evidenced by their VAS itch scores (Table 5-1). Therefore, 
correlating VAS itch scores and nerve measurements has no biological significance in 
controls and so was not performed. In cases, VAS itch score for the average itch in the 
preceding week of the study visit represents the most accurate reflection of the true itch 
state of the subjects. This is because itch in uremic pruritus can be paroxysmal and show 
day-to-day variation from our clinical experience and reports in the literature 
(Yosipovitch et al., 2001). Therefore, permutation correlation analysis was performed 
between nerve measurements and VAS score for the average itch in the preceding week.   
 
PDNL/mm, %PD-CGRP(+) and %PD-NPPB(-)/CGRP(+) all were negatively correlated 
with VAS-average itch preceding week (Table 5-17). These findings are consistent with 
the significant decrease of PDNL/mm, %PD-CGRP(+) and %PD-NPPB(-)/CGRP(+) in 
cases compared to controls. Consistent with the above, %CGRP that was NPPB(-) also 
  
82 
correlated negatively with VAS-average itch preceding week. Taken together, these data 
suggest that loss of papillary dermal CGRP nerves may contribute to augmented itch in 
uremic pruritus patients by loss of an itch-inhibition signal. In accordance with the 
negative correlation between VAS-average itch preceding week and %PD-
CGRP(+)/NPPB(-), VAS- average itch preceding week positively correlated with %PD-
CGRP(+)/NPPB(+); which is of uncertain biological significance, given the negligible 
number of CGRP(+)/NPPB(+) nerves in cases.  
 
The contribution of NPPB-expressing nerves to uremic itch is ambiguous. %PD-
NPPB(+)/SP(-) was significantly positively correlated with VAS-average itch preceding 
week (CC= 0.38, p= 0.04), whereas %PD-NPPB(+) was positively correlated with VAS- 
average itch preceding week without statistical significance (CC= 0.24, p= 0.14). Given 
the virtual absence of NPPB(+)/SP(+) nerves in cases, these data are inconclusive and 
suggest a larger sample size may be needed to obtain statistical significance. 
 
IENF, IENL/mm and %Epi negatively correlated with VAS-average itch preceding week. 
However, IENF, IENL/mm and %Epi did not show significant differences in cases 
compared to controls (Table 5-14). These data raise the possibility that epidermal nerve 
fibers may normally inhibit itch and loss of these nerves contributes to the severity of 
uremic pruritus. IENF, IENL/mm and %Epi did not correlate with cowhage-induced itch 
sensations in either cases or controls. Thus, if epidermal nerve fibers inhibit itch 
sensation, our data suggest that uremic pruritus itch signaling pathways are multifactorial, 
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and epidermal itch inhibition is silencing a non-protease-dependent itch signaling 
pathway contributing to uremic pruritus.   
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Table 5-17 Correlation of Nerve Measurements and VAS-Average Itch Preceding 
Week in Cases 
Cases 
CC*-VAS* (average 
itch preceding week) 
P value-VAS (average itch 
preceding week) 
IENF* -0.46 0.01 
IENL*/mm -0.61 0.0004 
%Epi  -0.46 0.01 
PDNL*/mm -0.53 0.003 
%PD* 0.46 0.01 
%PD-CGRP* (+)  -0.37 0.03 
%PD-SP* (+) -0.19 0.17 
%PD-NPPB* (+) 0.24 0.14 
%PD-NPPB(+)/CGRP(-)  0.23 0.16 
%PD-NPPB(-)/CGRP(+) -0.48 0.004 
%PD-NPPB(+)/CGRP(+) 0.14 0.27 
%PD-NPPB(+)/SP(-) 0.38 0.04 
%PD-NPPB(-)/SP(+) -0.27 0.1 
%PD-NPPB(+)/SP(+) 0.31 0.07 
%NPPB that is CGRP(-) -0.17 0.20 
%NPPB that is CGRP(+) -0.32 0.07 
%CGRP that is NPPB(-) 0.36 0.04 
%CGRP that is NPPB(+) -0.36 0.04 
%NPPB that is SP(-) -0.25 0.11 
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%NPPB that is SP(+) 0.06 0.39 
%SP that is NPPB(-) 0.25 0.12 
%SP that is NPPB(+) -0.25 0.12 
*CC: Correlation Coefficient 
  VAS: Visual Analogue Scale 
  IENF: intraepidermal nerve fiber 
  IENL/mm: Intraepidermal nerve length/mm epidermis 
  PDNL/mm: Papillary dermal nerve length/mm epidermis 
  PD: Papillary Dermis 
  CGRP: Calcitonin Gene Related Peptide 
  SP: Substance P 
  NPPB: Natriuretic Polypeptide Precursor B 
 
5.6.3 Correlation of Hemodialysis Duration and VAS-Average Itch Preceding Week  
There was no significant correlation between hemodialysis duration and VAS itch scores 
in all subject or in case-only groups. This was consistent with the result that there was no 
difference in hemodialysis duration between cases and controls.  
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Table 5-18. Correlation of Hemodialysis Duration and VAS-Average Itch Preceding 
Week in All Subjects 
All subjects CC-Hemodialysis Duration 
P value-Hemodialysis 
Duration 
VAS- average itch preceding week 0.22 0.14 
  
Table 5-19. Correlation of Hemodialysis Duration and VAS-Average Itch Preceding 
Week in Cases 
Cases 
CC-Hemodialysis 
Duration 
P value-Hemodialysis 
Duration 
VAS- average itch preceding week 0.16 0.22 
 
5.6.4 Correlation of Hemodialysis Duration and Cowhage-Spicule Induced Itch in 
All Subjects 
There was no correlation between cowhage-induced itch and hemodialysis duration in all 
subjects (Table 5-20).  
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Table 5-20. Correlation of Hemodialysis Duration and Cowhage-Spicule Induced 
Itch in All Subjects 
All subjects CC-Hemodialysis Duration P value-Hemodialysis Duration 
AUC itching 0.19 0.19 
peak itch 0.26 0.12 
total time itch 0.14 0.26 
time to peak itch -0.008 0.49 
AUC: Area Under the Curve 
 
5.7 Images of Multi-Label Immunohistochemistry Staining 
5.7.1 Specificity of Immunohistochemical Staining of a Primary Antibody Raised to 
Pre-proNPPB1-134 in Human Ventricle and Human Skin 
In equine atrium, immunohistochemistry detected NPPB-like expression within secretory 
granules of cardiomyocytes (Figure 5-1, Figure 5-2; Mifune and Richter, 1995). In our 
study, we obtained an as-of-yet commercially unavailable rabbit antibody raised to the 
full-length human NPPB protein (pre-proNPPB1-134). Using human cardiac tissue, we 
identified NPPB/NPPB precursor expression in secretory granules (Figure 5-3). This 
expression was not present when (a) the primary antibody was omitted (data not shown) 
or (b) the primary antibody was pre-incubated with the full-length immunizing peptide 
(pre-proNPPB1-134) (Figure 5-3). This expression persisted when the primary antibody 
was pre-incubated with the active peptide, NPPB1-32. We then utilized this antibody in 
human skin from subjects without pruritus and identified a population of primary 
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cutaneous nerves (as identified by PGP9.5 antibody staining, a pan-neuronal marker) that 
expressed NPPB/NPPB precursor (Figure 5-5). Again, this human skin staining was lost 
with either omission of the primary antibody or pre-incubation with the full-length 
immunizing peptide (pre-proNPPB1-134) (Figure 5-4). Importantly, the human skin 
staining persisted when the primary antibody was pre-incubated either with a non-
specific protein (GRP) (data not shown) or the active peptide, NPPB1-32 (Figure 5-4). 
Together, these observations indicate this primary antibody specifically identifies in 
human skin the N-terminal component of the full-length NPPB peptide precursor.    
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Figure 5-1. Secretory Granules of NPPB-like Expression in Cardiomyocytes (Mifune 
and Richter, 1995). 
 
In this electron microscope image, secretory granules are the dense circles of various 
sizes and are found in the perinuclear region predominantly at the poles of the elongated 
nucleus, the. (N:Nucleus). Scale bar: 1μm.(Figure from Mifune and Richter, 1995; legend 
adapted from Mifune and Richter, 1995) 
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Figure 5-2. NPPB-like Expression Within Secretory Granules of Cardiomyocytes 
(Mifune and Richter, 1995). 
 
Electron microscope image of double immuno-gold labeling of equine atrium. Large gold 
particles (15 nm in diameter) demonstrate IR- hCDD/ANP and small gold particles (5 nm 
in diameter) demonstrate IR-pBNR. Most of the secretory granules show both large and 
small gold particles (single arrow-head). Few show small gold particles only (double 
arrow-head). (N: nucleus, G: Golgi apparatus, IR: immunoreactive, hCDD/ANP: human 
cardiodilatin/Atrial Natriuretic Peptide, pBNP: porcine Brain Natriuretic Peptide). Scale 
bar, 100nm. (Figure from Mifune and Richter, 1995; legend adapted from Mifune and 
Richter, 1995) 
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Figure 5-3. Specificity of NPPB/NPPB Precursor Antibody Staining in Human 
Cardiomyocytes. 
 
(a-c) NPPB/NPPB precursor antibody alone, (d-f) NPPB/NPPB precursor antibody pre-
incubated with immunizing peptide (pre-proNPPB1-134) or (g-i) pre-incubated with 
NPPB1-32. NPPB/NPPB precursor antibody detection used Alexa568 (generates a 
fluorescence signal only in the TRITC channel). (a,d,g) TRITC channel. (b,e,g) FITC 
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channel images of sections in (a,d,g respectively). (c,f,i) Composite of Alexa 568 and 
FITC channels. (a-i) Arrows show secretory granule staining visible only in the TRITC 
channel (a and g) that is abolished by pre-incubation with immunizing peptide (d) but not 
with NPPB1-32 (g). Arrowheads show endogenous autofluorescence from lipofuscin, 
visible in both the TRITC and FITC channels with (d-f; g-i) and without (a-c) 
immunizing peptides. p-pN1-134, pre-proNPPB1-134; FITC AF, FITC autofluorescence; 
N1-32,NPPB1-32. Scale bars, 100μm. 
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Figure 5-4. Specificity of NPPB/NPPB Precursor Antibody Staining for Papillary 
Dermal Nerves in Human Skin. 
 
Double immunohistochemistry of PGP9.5 antibody with (a–c) NPPB/NPPB precursor 
antibody pre-incubated with immunizing peptide (pre-proNPPB1-134); or (d–f) 
NPPB/NPPB precursor antibody pre-incubated with NPPB1-32. (a–c) following pre-
incubation with immunizing peptide, asterisks highlight (a) the absence of NPPB/NPPB 
precursor antibody staining of (b) PGP9.5(+) nerves. (c,d) Arrows show co-localization 
of (d) NPPB/NPPB precursor staining with (e) PGP9.5-positive cutaneous nerves that 
terminate near the DEJ. (c,f) Composite images of (a&b; d&e, respectively). p-pN1-1-
134, pre-proNPPB1-134; N1-32, NPPB1-32. (a–f) Dashed lines indicate the dermoepidermal 
junction. Scale bars, 100μm. 
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5.7.2 Characterization of NPPB Positive Cutaneous Nerves in Subjects' Skin 
Mishra and Hoon demonstrated that in mice, only a minority of NPPB-positive neurons 
co-stained with substance P, that ~25% co-stained with calcitonin gene related peptide 
(CGRP), and that 50% of them co-stain with Neuromedin B (Mishra and Hoon, 2013). 
We reported the percentage of such nerves that co-express peptidergic markers (SP and 
CGRP), that are C- and/or Aδ-fibers in section 5.5.2.1. Here we provide examples of 
triple immunohistochemical experiments with NPPB, PGP9.5, and either SP or CGRP in 
uremic pruritus and control skin, respectively. NPPB commonly co-stained with CGRP, 
whereas, NPPB rarely co-stained with SP.  
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Figure 5-5. Multi-label (NPPB, CGRP, and PGP9.5) Immunohistochemical 
Localization of Peptidergic Nerves in Control Skin. 
  
(a,d) NPPB staining (red); (b,e) CGRP staining (blue); (c,f) composite of NPPB, CGRP 
and PGP9.5 (green) triple staining. Arrows show papillary dermal nerves positive for 
CGRP. Double arrows show papillary dermal nerves positive for NPPB. Arrowhead 
shows nerves positive for both NPPB and CGRP. E: epidermis; D: dermis; white line, 
dermoepidermal junction. Similar results were observed in uremic pruritus skin (data not 
shown). Scale bar: 50μm.  
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Figure 5-6. Multi-label (NPPB, SP, and PGP9.5) Immunohistochemical Localization 
of Peptidergic Nerves in Uremic Pruritus Skin.  
 
(a,d) NPPB staining (red); (b,e) SP staining (blue); (c,f) composite of NPPB, SP and 
PGP9.5 (green) triple staining. Arrows show nerves positive for SP. Double arrows show 
nerves positive for NPPB. Similar results were observed in control skin (data not shown). 
E: epidermis; D: dermis; white line, dermoepidermal junction. Scale bar: 50μm.  
 
5.7.3 Characterization of TRPV-1 Positive Nerves in the Skin of Uremic Pruritus 
and Controls.  
As described in section 5.5.2.2 and 5.5.2.3, there was no difference in TRPV-1 positive 
nerves in the epidermis of cases with uremic pruritus compared to controls. TRPV-1 
positive nerves were decreased in the dermis of cases with uremic pruritus compared to 
controls.  
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Figure 5-7. Immunohistochemical Localization of TRPV-1 in Peptidergic Nerves in 
Uremic Pruritus and Control Skin.  
 
(a) Uremic Pruritus; (b) Control. E: epidermis; D: dermis; white line, dermoepidermal 
junction. Scale bar: 50μm.  
 
 
 
  
98 
CHAPTER 6. DISCUSSION 
Uremic pruritus is a paroxysmal symptom that occurs in the setting of chronic renal 
failure. Uremic pruritus is a misnomer as the pruritus is not secondary to elevated serum 
urea levels. In fact, the clinical entity of uremic pruritus is multifactorial, and its causes 
and treatments have evolved over time as a consequence of advances in dialysis 
technique. Lower than normal iron, vitamin B12, and/or hemoglobin levels are common 
in end-stage renal disease, and their correction relieves itch in a subset of these patients. 
Similarly, elevated serum parathyroid hormone (PTH), calcium and phosphorus are also 
causes of intractable pruritus, relieved either by parathyroidectomy and/or oral medicine 
to lower phosphorus, and/or PTH levels (Chou et al., 2000). Finally, xerosis (i.e., dry 
skin) is very common in ESRD patients, and untreated could cause pruritus. Optimal skin 
care regimen based on diligent moisturizing dramatically relieves this itch.  
 
Given this diversity of causes of pruritus that can occur in the setting of end-stage renal 
disease and so be encompassed by the generic clinical term “uremic pruritus,” we sought 
to define more specifically this term for this study. Subjects with uremic pruritus had itch 
as follows: 1) arising from end-stage renal disease; 2) persistent despite proper dialysis 
(on dialysis for at least 6 months with a Kt/V>1.20 (Kt/V is defined as the dialyzer 
clearance of urea (K) multiplied by the duration of the dialysis treatment (t, in minutes) 
divided by the volume of distribution of urea in the body (V, in mL), which is 
approximately equal to the total body water, corrected for volume lost during 
ultrafiltration. We used the KDOQI guidelines of > 1.2 being considered "adequate" to 
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rule out a patient having pruritis due to being underdialyzed.)); 3) persistent despite 
serum chemistries within the acceptable range (average for the last 6 months) according 
to National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) 
guidelines; and 4) not attributable to other systemic or skin conditions. 
 
In our study, 12 subjects with uremic pruritus, as defined above, were recruited according 
to our inclusion and exclusion criteria (see Appendix II), which made up about 10% of 
the hemodialysis population in this single dialysis facility. From the recent literature, the 
prevalence of uremic pruritus ranged from 40% to 60% in the population on adequate 
hemodialysis (Pisoni et al., 2006; Duque et al., 2006). In these studies, uremic pruritus 
was more broadly defined, only requiring an index for proper dialysis but not excluding 
subjects with abnormal serum chemistries or dry skin. For example, in the international 
Dialysis Outcomes and Practice Patterns Study (DOPPS), serum phosphorus level was 
higher than the level allowed in our study based on the KDOQI guideline. Conversely, in 
our study, the stricter and narrower definition of uremic pruritus and high quality of the 
dialysis regimen resulted the lower 10% prevalence rate in the single utilized dialysis 
facility. This 10% prevalence rate still fell within the 5%–75% inter-facility range 
reported in multi-facility DOPPS study (Pisoni et al., 2006). 
 
The medical literature indicates uremic pruritus is independent of gender, ethnicity, age, 
and duration of hemodialysis. Our data are consistent with literature in that uremic 
pruritus was not related to duration of hemodialysis. The intensity of uremic itch ranges 
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from sporadic to restless. The frequency of uremic pruritus ranges from intermittent to 
persistent. This vacillating quality was reflected by the three VAS itch scores obtained in 
this study: VAS-average itch preceding week, VAS-worst itch preceding week, and 
VAS-itch day of visit. In our study subjects, VAS-worst itch preceding week was the 
same or higher than VAS-average itch preceding week, while VAS-itch day of visit was 
either lower than, higher than, or similar to VAS-average itch preceding week.  
 
Uremic pruritus may be generalized or localized, and predominantly affects the back 
(70%), followed by abdomen (46%), head (44%), and arms (43%) (Gilchrest et al., 
1982). This was also consistent with our clinical observation that uremic pruritus was 
present on the back of all subjects with itch. In our study, we purposely excluded subjects 
with itch only involving the lower legs to exclude the confounding factors of dry skin and 
ESRD-related length-dependent small fiber neuropathy (Lauria et al., 2010).  
 
Uremic pruritus adversely affects quality of life. The DOPPS study found that HD 
patients with moderate-to-extreme pruritus were more likely to feel drained and have 
poor sleep quality, depression, and lower mental and physical composite scores of quality 
of life than subjects with no or mild pruritus (Pisoni et al., 2006). In accordance with the 
result from this large cohort study, the quality of life in our case group was statistically 
significantly worse than that of control group using the frequency version of itchy QoL 
questionnaire (Desai et al., 2008). Our results confirm that our subjects experienced 
uremic pruritus that was very symptomatic and adversely affected both emotions and 
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social functioning. 
 
Uremic pruritus is a type of chronic pruritus. Two pathways can cause chronic itch: 
central sensitization and peripheral sensitization. We sought evidence for three types of 
central sensitization in the uremic pruritus population: mechanical and non-noxious 
touch-to-itch, pin-prick type pain-to-itch, and heat pain-to-itch. Our data definitively 
excluded mechanical and non-noxious touch-to-itch central sensitization. Technical 
issues rendered our data inadequate to assess for either pin-prick pain-to-itch or heat 
pain-to itch. Our study utilized a set of weighted needles shown to efficacious to induce 
incrementally increase pain scores in the forearms and scalps of healthy subjects without 
ESRD or dialysis. In both the uremic pruritus and control groups, pin-prick-induced pain 
did not increase as the weight load of the needles increased.  This failure of the weight set 
to induce incrementally increasing pain may have resulted from the weights being too 
light for the thick back skin as compared to forearm/scalp skin and/or from the 
abnormally high mechanical pain threshold of this unique study population, accustomed 
to needle pricks from much larger and wider needles used routinely in dialysis. Future 
studies would determine the appropriate weight set reference range for back skin in 
healthy, age- and sex-matched subjects without ESRD and without dialysis.  
 
Non-sedative histamine receptor antagonists are rarely efficacious for relieving uremic 
pruritus. Therefore, uremic pruritus may be mediated through a neuroanatomic pathway 
that is specific for non-histamine dependent itch. Mucunain, a cysteine protease 
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concentrated in the tips of cowhage plant spicules, was utilized to test the protease-
mediated, histamine- independent itch pathway. In our study, we have demonstrated that 
cowhage-induced total itch, expressed as area under the curve (AUC)-itching, and peak 
itch were significantly higher in cases than controls. No differences were found in 
prickling/tingling or burning sensation induced by cowhage spicules between cases and 
controls. This novel finding implies that augmented activity via a protease-dependent, 
histamine-independent neuroanatomic pathway is involved in the pathophysiology of 
uremic pruritus.  
 
Few studies have investigated changes in cutaneous innervations in subjects with uremic 
pruritus. We sought to investigate if uremic pruritus, as we narrowly defined it (see 
Discussion Chapter in thesis), arose in the setting of alterations in epidermal and papillary 
dermal cutaneous innervation. We utilized the pan-neuronal marker PGP9.5 and TRPV-1, 
both of which are expressed in histamine-dependent and histamine-independent itch 
nerve pathways. Histamine-independent itch nerves in the skin are mechanical and heat 
sensitive (CMH) C- and Aδ- fibers that terminate in the papillary dermis and in the 
epidermis. The neuroanatomical site of termination of histamine-dependent, mechanically 
insensitive (CMiHis+) C-fibers are unknown. In our study, the length of papillary dermal 
nerves per mm epidermis staining positively for TRPV1 antibodies was statistically 
significantly lower in uremic pruritus group than that in controls. Specifically, nerves 
expressing the CGRP peptide were statistically significantly lost in uremic pruritus group 
compared to the control group and were lost in an amount sufficient enough to account 
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for the lost population of papillary dermal TRPV-1 positive nerves.   
 
CGRP-expressing cutaneous nerves have been shown to mediate nociceptive heat and 
pain in animal models (Mogil et al., 2005; Sun et al., 2004). Experiments in different 
animal and human studies have shown that cutaneous pain stimuli inhibit coincident 
cutaneous itch (Ward et al., 1996; Green et al., 2006). We postulate that loss of 
cutaneous-derived itch inhibition from the loss of CGRP-expressing pain nerves 
contributes to itch in uremic pruritus. Correlation studies further supported this 
hypothesis. The ratio of CGRP positive nerves in the papillary dermis is negatively 
correlated with VAS-average itch last week in uremic pruritus subjects. CGRP positive 
nerves that did not co-stain with NPPB (more than 80% of all CGRP positive nerves) 
were decreased in the uremic pruritus, and also correlated negatively with VAS-average 
itch last week in uremic pruritus subjects. This implies that loss of CGRP-positive nerves, 
specifically the subset that does not co-express NPPB, contributes to uremic pruritus and 
itch intensity in uremic pruritus. Furthermore, in uremic pruritus subjects, the ratio of all 
CGRP-positive nerves in the papillary dermis and those that did not express NPPB, were 
both negatively correlated with AUC-itching from cowhage stimulation. This implies that 
loss of CGRP nerves contributed to augmented cowhage-induced itch. In conclusion, we 
propose that CGRP(+)/NPPB(-) nerves in the papillary dermis signal pain and  may 
inhibit histamine-independent, protease-mediated itch in normal skin. Loss of these 
nerves in uremic pruritus results in a loss of this itch inhibition, contributing to 
augmented cowhage signaling and itch in uremic pruritus.  
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NPPB was proposed to be involved exclusively in the cutaneous itch pathway (Mishra 
and Hoon, 2013). In our lab, for the first time, NPPB was found to be expressed in the 
peripheral endings of primary afferent nerves in human skin. The majority of NPPB 
nerves co-stained with CGRP peptide. In our study, NPPB-positive nerves were 
decreased, specifically those that co-stained with CGRP, with the preservation of NPPB-
positive nerves that did not co-stain with CGRP. Thus, we conclude that loss of NPPB 
nerves in the papillary dermis resulted from loss of the CGRP nerve population. NPPB 
nerves comprised a very small percentage of papillary dermal nerves, 1.8% in controls, 
0.8% in cases. This is consistent with recent RNA-sequencing data from human 
trigeminal ganglia (Goswami et al., 2014). Moreover, almost all NPPB nerves that co-
stained with CGRP were lost in cases. Thus, the correlation between NPPB ratio and 
other measurements in the uremic pruritus population was not plausible. In controls, 
%PD-NPPB and %PD-NPPB(+)/CGRP(+) were both positively correlated with peak itch 
induced by cowhage spicules. In conclusion, NPPB nerves were involved in histamine-
independent, protease-mediated itch sensation.  
 
The contribution of epidermal nerve innervation to uremic pruritus is not well-
understood. Two articles published in the 1980s reported conflicting results: one found 
that epidermal sprouting was seen in all patients on hemodialysis independent of itch 
status (Stahle-Backdahl, 1989) and the other found that there was a reduction in 
epidermal innervation in ESRD patients compared to healthy controls (Fantini et al., 
1992). Both of these studies had serious enough methodological flaws to call into 
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question the significance of their findings. Both studies utilized 14μm sections, which is a 
thickness that is suboptimal for evaluating nerve fiber density. In the Stahle-Backdahl 
study, biopsies were taken from finger tips and lower legs and only visually qualitative 
assessment of nerve number was performed. In the Fantini et al. study, biopsies were 
taken from volar aspect of forearms, and assessment of nerve amount used a "semi-
quantitative evaluation" where the number of neuron-specific enolase (NSE)-
immunoreactive (IR) nerve fibers was subjectively classified into 
absent/moderate/numerous in epidermis or dermis. This evaluation relied only upon 
visual inspection and statistical analysis was not performed when comparing the values 
for ESRD subjects on hemodialysis and healthy controls. 
 
We investigated epidermal nerve innervation using TRPV-1 and found it was not 
statistically significantly decreased in uremic pruritus subjects. However, in the 
correlation analysis, intraepidermal nerve fiber density and intraepidermal nerve fiber 
length/mm epidermis, were both negatively correlated with VAS-average itch last week 
in the uremic pruritus population. This implies that epidermal innervation contributes to 
the pathophysiology of uremic pruritus and the intensity of itch in uremic pruritus. Loss 
of epidermal innervation paralleled hypoalgesia in normal skin, indicating these nerves 
signal at least pain (Nolano et al., 1999). Taken together, we postulate that in uremic 
pruritus, epidermal nociceptor-mediated itch inhibition is one mechanism to compensate 
for the loss of papillary dermal CGRP-mediated itch inhibition. 
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Our study was observational and while could show correlations, could not prove causal 
relationships between the above described neuroanatomic changes and uremic pruritus. 
Rodent models are one class of future studies that could be used to prove causation. 
However, rodent skin has inherent differences compared to human skin that may impede 
their use for such studies. For example, in rodents, CGRP positive nerves comprise a 
much larger subset of all papillary dermal nerves than in human skin, and unlike humans, 
CGRP(+) nerves are present in the epidermis of rodents. Accordingly, existing rodent 
studies implicate CGRP-expressing nerves in both pain and itch pathways, and this may 
be a consequence of the expanded expression pattern in rodents versus humans. Future 
studies could examine the skin of other animals to identify a model whose cutaneous 
CGRP population mirrors that of humans. In humans, technical methodology does not 
currently exist to selectively ablate CGRP-expressing cutaneous nerves. Alternatives in 
humans include administration of systemic acting CGRP and/or synthetic molecules that 
activate the CGRP receptor, as our theory predicts such molecules should reduce uremic 
pruritus. Interestingly, amylin, a peptide co-secreted with insulin from pancreas, is also 
an agonist of CGRP receptor (Poyner et al., 2002). The synthetic analog (Pramlintide) 
was used to treat diabetes (Ratner et al., 2004), and an oral form has been investigated 
(Andreassen et al., 2014). Anti-pruritic effects of these synthetic CGRP receptor agonists 
have not been investigated. Conversely, administration in humans of CGRP receptor 
antagonists should enhance experimental and possibly clinical pruritus. Of the above 
mentioned alternatives, CGRP receptor antagonists are under investigation in humans to 
treat migraines. However, these antagonists do not cross blood brain barrier, precluding 
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them from reaching receptors in the dorsal horn of spinal cord where presumably the 
CGRP is acting to inhibit itch. Intrathecal injection of CGRP receptor antagonists could 
overcome the blood brain barrier impermeability but is not an ethical experimental design 
in humans. While the causes of uremic pruritus are multi-factorial, our data raise the 
possibility of a novel therapeutic approach to treating uremic pruritus: stimulation of 
CGRP-mediated input into the dorsal horn of the spinal cord. Therefore, these data 
warrant additional experiments in appropriately chosen animal models and in humans 
with existing and novel CGRP receptor agonists to investigate and extend further our 
findings. 
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CHAPTER 7. CONCLUSION 
This study was motivated by the clinical observation that in some patients with end-stage 
renal disease on dialysis, uremic pruritus persists despite correction of all known 
metabolic and dermatologic causes. Although placebo effects cannot be entirely 
excluded, the efficacy of narrow-band UVB to relieve uremic pruritus suggested that 
uremic pruritus may arise from a cutaneous source. In this regard, uremic pruritus occurs 
in the absence of skin inflammation, suggesting an alteration in cutaneous nerve signaling 
pathways. Unlike other studies published to date, we investigated the innervation of the 
epidermis and papillary dermis in subjects with uremic pruritus compared to age- and 
sex-matched controls, with both study groups having ESRD on effective hemodialysis, 
including without serum or metabolic abnormalities. Our study generated several novel 
findings: We found evidence for sensitization of a protease-mediated, histamine-
independent cutaneous itch pathway in uremic pruritus. We propose that this augmented 
protease-mediated itch and uremic pruritus occur at least in part from central 
sensitization. Specifically, we found that both augmented protease-mediated itch and 
uremic pruritus occurred in the setting of the partial loss of CGRP(+)/NPPB(-) nerves in 
the papillary dermis. We hypothesize that these CGRP(+)/NPPB(-) nerves mediate pain 
in normal human skin, that this cutaneous pain input inhibits coincident cutaneous itch in 
the dorsal horn of the spinal cord, and that loss of these nerves contributes to augmented 
protease-dependent itch and uremic pruritus in our study population. 
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This study is a first step in investigating the role of peripheral nerves in the 
pathophysiology of uremic pruritus and more broadly, chronic pruritus. Causal studies 
are required to prove that the loss of CGRP-expressing papillary dermal nerves 
mechanistically explains uremic pruritus. Additional research is required to determine the 
factors causing the selective loss of this nerve population. Future research is also needed 
to examine if loss of papillary dermal CGRP nerves occurs in other forms of chronic itch 
without skin inflammation.  
 
In conclusion, for the first time, we found anatomic and functional changes in the skin of 
subjects with uremic pruritus: loss of papillary dermal CGRP nerves and sensitization to 
cowhage-induced histamine-independent itch. We believe that this knowledge gained will 
contribute to future efforts to generate more effective treatments for this debilitating 
symptom. 
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APPENDICES 
Appendix I. Screening Questionnaire 
Phone Date: _________________________________________ 
 
Thank you for your interest in our study about why the skin itches in subjects with end-
stage renal disease and on hemodialysis.  We would like to let you know this study 
involves 1 clinical visit to Boston Medical Center, Dept. of Dermatology. At this visit, 
you will fill out questionnaires about if your skin itches, undergo testing to see how 
sensitive your skin is to warm heat, touch, prick, and itch, and then have a single small 
piece of skin from either your abdomen or back cut out which is called a skin biopsy for 
which you will be paid. If these procedures are OK with you, I would like to ask you a 
few questions to see if this study is a good fit for you and if you are a good fit for this 
study. 
 Section I:  Inclusion/Exclusion Criteria Script of anonymous screening questions without 
collection of personal health information 
Inclusion criteria: 
1.  Age 18 years or older:   yes       OR      no 
2.  Do you have end-stage renal disease:  yes    OR    no? 
3.  Are you on hemodialysis?   Yes   OR  no?  
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4.  Does your skin itch?  If so, how much in a given week on a scale of 0–100 with 0 
being no itch and 30 being just at that amount of itch that makes you want to scratch and 
100 being worst imaginable itch? 
4.  Are you willing to come to the Dermatology building for  the 1 time study visit?  YES 
or NO? 
Exclusion Criteria: 
(1) Do you have a history of any other type of skin disease now or in the past (per verbal 
report of subject/control):      yes       OR       no 
(2) Are you able to read and then answer written questions about your itch?  Yes       OR       
no 
 (3) Do you have a history of allergy and/or history of adverse reaction to lidocaine used 
for the skin biopsy:     yes       OR       no 
 (4)  If female:  are you pregnant or do you think you might be pregnant?     
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Appendix II. Inclusion and Exclusion Criteria 
Inclusion Criteria  
• Individuals 18yrs old or older. 
• Individuals with chronic (6 weeks or greater) of generalized pruritus, rated on a 
VAS scale as 30 or more (out of 100), that started after diagnosis of chronic 
kidney disease (CKD)( this is only for cases group, not for controls). 
• Individuals with underlying ESRD on hemodialysis for at least 6 months with 
Kt/V ratio of >1.2.  
Exclusion criteria 
• Individuals with known psychiatric, neurologic, or substance abuse disorders that 
would interfere with cooperation with the requirements of the trial. 
• Individuals with an allergy and/or history of adverse reaction to lidocaine used for 
the biopsy. 
• Women who are pregnant and/or breast-feeding. 
• Individuals who are taking opioid derivatives, such as Buprenorphine, Codeine, 
Oxycodone, Dextropropoxyohene, Methadone, Hydromorphone, Tramadol, 
Butorphanol, Fetanyl, Alfentanil, Sufentanil, Remifentanil, Morphine, 
Meperidine, Nalmefene, Naltrexone, Naloxone and Nalfurafine. 
• Individuals with psychologic cause(s) of pruritus. 
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• Individuals with a primary skin disease (e.g. atopic dermatitis, cutaneous T-cell 
lymphoma) and/or other systemic disease that can cause pruritus. 
• Individuals with pruritus where the pruritus is clinically attributed to an existing 
disease, such as abnormal PTH, Calcium, Phosphorus levels (per KDOQI 
guideline), VitB12 deficiency, Iron deficiency, Hgb<9g/dl,  or active thyroid 
disease.  
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Item 
no.  
Description of the item 
In the past 1 week, how frequently have 
you experienced the following…..  
Scoring 
 
1 My itchy skin condition bleeds [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
2 My skin hurts because of my itchy skin 
condition  
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
3 My itchy skin condition burns or stings [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
4 I get scars from my itchy skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
5 I need to scratch my itchy skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
6 Temperature/seasonal changes aggravate my 
itchy skin condition 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
7 I spend a lot of money treating my itchy skin 
condition 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
8 My itchy skin condition makes it hard to work 
or do what I enjoy 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
9 My itchy skin affects my interaction with 
others 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
10 My itchy skin condition affects how well I 
sleep 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
11 My itchy skin condition often makes it 
difficult to concentrate 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
12 My itchy skin condition limits the types of 
clothes I can wear 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
13 My itchy skin condition forces me to buy 
special soaps, detergents, and lotions 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
Appendix III. Itchy Quality of Life Questionnaire 
Itchy Quality of Life 
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14 I am frustrated by my itchy skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
15 I am embarrassed by my itchy skin condition [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
16 My itchy skin condition drives me 
crazy/nuts 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
17 My itchy skin condition makes me feel 
angry or irritable 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
18 My itchy skin condition makes me feel 
depressed or sad 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
19 I worry about what other people think about 
me because of my itchy skin condition 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
20 I worry that the itching will last forever [ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
21 I feel self-conscious because of my itchy 
skin condition 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
22 My personality has changed because of my 
itchy skin condition 
[ ] Never      [ ] Rarely     [ ] Sometimes    
[ ] Often     [ ] All the time 
   1 = never, 2 = rarely, 3 = sometimes, 4 
= often, 5 = all the time                                                                                                                                     
Total symptoms score = avg of 
responses  (1–6)  
Total functioning  score = avg of 
responses (7–16) 
Total emotions score (17–22) = avg of 
responses (17–22) 
  
116 
Appendix IV. Three VAS Itch Questionnaires 
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Appendix V. Description of Sensations and Instructions on How to Use a Computer 
to Assess Cowhage-Induced Itch  
 
Date:   
Name of Experimenter:                                                 
Patient ID #:  
 
 Subject is given the description of cutaneous sensations 
Cutaneous Sensation Qualities 
 
BURNING:  A sensation most often associated with thermal burns and sun burns, but 
can also result from other stimuli, such as skin abrasions, strong cold, and chemical 
irritants. Can be either painful or non-painful, and may or may not be accompanied by a 
temperature sensation. 
 
STINGING: A sharp, well-localized sensation (e.g., as from an insect bite) that can be 
painful or non-painful, and may or may not be accompanied by a temperature sensation. 
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PRICKING: A sharp, well-localized sensation similar to stinging, but brief or 
intermittent (e.g., as from a needle “prick”), which may or may not be painful. 
 
ITCHING: A generally persistent sensation that when sufficiently strong provokes the 
desire to scratch. 
 
TINGLING: A lively “pins-and-needles” sensation 
 
WARM: The sensation of mild heating. 
 
HOT: The sensation associated with temperatures that are more than warm but is not 
necessarily painful.  
 
NUMBNESS: The diffuse (i.e., “fuzzy”) sensation produced during the onset or offset of 
an anesthetic (i.e., Novocaine). NOT the absence of sensation. 
 
ICY: A sensation like that produced by touching ice to the skin. 
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ACHE: A dull, uncomfortable sensation that fluctuates in strength, appears to come from 
below the skin’s surface, and is usually difficult to localize. 
 
TICKLE: A light, attention-grabbing sensation of contact or movement; different from 
itch but may also provoke the desire to rub or scratch.  
 
PAIN: Any sensation that ‘hurts’ and to which you might respond by saying “ouch!”   
 
Alloknesis: Enhanced itch evoked by light touch or enhancement of an ongoing itch by 
light touch. If skin is lightly stroked with a cotton swab it does not produce sensation of 
itch. It may be ticklish but does not evoke itch. If the light stroking with cotton swab 
induces itch or exacerbates an ongoing itch then it is called alloknesis. 
 
 Hyperalgesia: Brief pricking of the skin by a 50µm tip von Frey filament that I am 
going to show you produces two sensations. The first sensation is a prickle or pricking 
pain this is followed about 1 second later by a second sensation of itch. If the pricking 
pain is enhanced (more than usual) that is called Hyperalgesia and if there is enhanced 
itch to the stimulus it is called Hyperknesis. 
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D 
Subject is given instructions for gLMS 
 Instructions for the generalized LABELED MAGNITUDE SCALE: 
 
You will be asked to rate the intensity of a variety of real and remembered sensations by 
indicating where they lie on a scale of all possible sensations. The scale contains 
commonly used terms like weak and strong, and the top of the scale is the strongest 
sensation of any kind that you can imagine experiencing.  
 
When you make your ratings you should use the terms just as you would in daily life. But 
do not limit your ratings to the terms themselves.  A good strategy is to first decide which 
term most closely describes the strength of a sensation, then fine-tune your rating by 
moving the cursor between that descriptor and the next most appropriate one. For 
example, if you think a sensation is about moderate, but a little bit stronger, you should 
move the cursor to the appropriate place just above moderate. If you think another 
sensation is more than just barely detectable but less than weak, you should move the 
cursor to the appropriate place between barely detectable and weak, and so on.   
It is important to emphasize that the top of the scale is "strongest imaginable", which 
represents the most intense--and therefore most painful--sensation that you can ever 
imagine experiencing. 
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Do you have any questions about how to use the scale? 
 
********************* 
 
Training Task 
 To acquaint you with the scale, I would like you to move the cursor to the place 
on the scale that best describes the intensity of the following remembered or imagined 
sensations (read aloud to subject): 
 
1. Washing your hands with cold water.  
2. A friendly tap on the shoulder. 
3. The itch of a mosquito bite. 
4. The warmth of a cat sitting on your lap. 
5. Stubbing your toe. 
6. A warm breeze on your face. 
7. Briefly touching a hot light bulb.  
8. Getting into a hot bath.   
9. An itch on your scalp.  
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10. Dipping your hand in scalding hot water. 
11. A cotton swab touched to your cheek.  
12. Pricking your finger with a needle. 
13. Putting a hat on your head. 
14. Knocking on a wooden door.  
15. Briefly touching an ice cube with a fingertip.  
16. Slamming a door on your finger. 
17. The summer sun on your face. 
18. The winter sun on your face. 
19. A bee sting. 
20. A fly landing on you arm. 
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E 
The purpose of the study and method of the experiment is explained to the subject 
Instruction for the experiment 
Instructions to subjects 
Sensation produced by cowhage 
Introduction: The purpose of this study is to measure the magnitude and duration of 
different kinds of sensations on your skin.   
 
The first and second tests will be combined and use a cotton swab and a series of 5 
weighted needles. The swab will be gently rubbed on your skin. After each trial of 
rubbing you will answer a yes or no question. Each weighted needle will be gently 
applied to your skin in such a way that does not cut your skin.  Each needle will touch 
your skin for 2 seconds. We will test your back or abdomen. You will NOT be allowed to 
look at the test site during this procedure. Each weight will be applied for a total of 5 
times. After each application, mark on the scale bar what you felt. For both the cotton 
swab and the needles, we are NOT asking you to record the sensations of touch or 
pressure. We want you to tell us about either pain or itch. Pain is different than touch or 
pressure because pain should feel like a sharp or slightly pricking or burning sensation. 
Itch is different than touch or pressure because itch should feel like a desire to scratch.  
 
Remember this is not a test. There are no wrong or right answers. All trials will have 
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touch or pressure but only some will have pain and/or itch. It is OK to feel no pain and/or 
no itch. Please describe what you feel as best as you can.   
 
The third will be the application of a heated metal rod to your skin. It is not hot enough to 
burn your skin. It will be applied to your skin for 10 seconds ONE time. It will be applied 
to your back or abdomen. You will may or may not feel the sensation of temperature/heat 
when it is placed on your skin. If you do feel temperature or heat, we are NOT asking you 
to record the ability to feel the temperature or the heat. We are asking you to mark on the 
scale bar the intensity of itch, pain, both, or none, that you felt with the heating sensation.  
 
Again, remember this is not a test. There are no wrong or right answers. It is OK to feel 
no pain and/or no itch. Please describe what you feel as best as you can.   
 
The fourth will be produced by a very superficial insertion of a cowhage spicule into the 
skin of your back or abdomen. Cowhage is a naturally occurring plant and the spicules 
are neither harmful nor is the insertion of spicule painful.  
 
You will use the labeled magnitude scale to rate the intensity of the sensations you feel. 
You will be prompted to rate three sensations in a sequence one after the other in 30 sec. 
The scale is going to repeat itself in the same sequence after every 30 seconds. You may 
or may not feel all the sensations you are prompted for so just rate 0 for any sensation 
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you do not feel. The first screen will ask you to rate the intensity of itch, so you will 
move the cursor to a place on the labeled magnitude scale which corresponds to the 
maximum intensity of Itch you have felt during the last 30 seconds and give your rating 
by clicking on that place. A window will appear after your click, asking you to confirm 
your rating. You can select “Yes” to confirm your rating or “No” to go back and change 
your rating. The second screen will ask you to rate pricking/stinging. Again you will 
move the cursor on the labeled magnitude scale to a point that corresponds to the highest 
intensity of pricking/stinging you have felt during the last 30 seconds and give your 
rating. The third screen will ask you to rate “burning” sensation in the same manner as 
you have rated itch and pricking/stinging.  
  
If you take more than 30 seconds to rate these sensations the scale will repeat itself and 
will come back to the first sensation, i.e. itch. You will also hear a beep just before every 
prompt. Please keep in mind that this is not a test, so there is no right or wrong answer.  
We are relying on your careful reports to discover what kinds of sensations are evoked by 
cowhage spicules.   
 
Do you have any questions? 
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Appendix VI. Recording Sheets for Pin-Prick Test 
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Appendix VII. Flyers             
Flyers for Cases 
Study of Cause of Itch that Happens with Hemodialysis  
Are you a male or female age 18 or older?  
Do you speak English? 
Do you have end-stage kidney disease? 
Are you on hemodialysis? 
Does your skin itch? 
 
Boston University School of Medicine, Department of Dermatology is currently enrolling 
people with end-stage kidney disease that are on hemodialysis and have itch, in a 
research study to determine what causes the itch in this setting.  
• We will ask you to answer some questions over the phone. 
• You may be asked to fill out a few surveys about your skin.  
• We will test your skin to see how sensitive it is to warm heat, pressure, and itch. 
• You will undergo 10 weeks of 3 times per week treatment in the Shapiro Center at 
Boston Medical Center, with light.   
• Lastly, we will take 1 small (6 mm wide; narrower than your smallest finger nail) 
sample of the skin either from your belly or your back.  
You can earn $50 for completing all study tasks and undergoing the skin biopsy.  
To find out more, contact our research team at katedu@bu.edu or 617-638-5574.  
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Flyers for Controls 
Study of Causes of Itch that Happens with Hemodialysis  
Are you a male or female age 18 or older?  
Do you speak English? 
Do you have end-stage kidney disease? 
Are you on hemodialysis? 
Does your skin NOT itch? 
 
Boston University School of Medicine, Department of Dermatology is currently enrolling 
people with end-stage kidney disease that are on hemodialysis but do NOT have itch, to 
be controls in a research study to determine what causes the itch in this setting.  
• We will ask you to answer some questions over the phone. 
• You may be asked to fill out a few surveys about your skin.  
• We will test your skin to see how sensitive it is to warm heat, pressure, and itch. 
• Lastly, we will take 1 small (6 mm wide; narrower than your smallest finger nail) 
sample of the skin either from your belly or your back.  
 
You can earn $50 for completing all study tasks and undergoing the skin biopsy.  
To find out more, contact our research team at katedu@bu.edu or 617-638-5574. 
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